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ABSTRACT 
The p53 tumour suppressor gene which is involved in the regulation of DNA 
replication and transcription, is reportedly mutated in approximately 50% of all human 
malignancies. Comparatively little information is available however, on the status of 
this gene in tumours of the uterine cervix, particularly in high risk populations. 
In this study cervical tumours from 101 Black South African women were examined 
for evidence of p53 mutations using loss of heterozygosity (LOH) as a screening 
procedure. The technique used was based on differences in PCR amplified variable 
numbers of tandem repeat sequences. Tumours were also examined for the presence 
of the human papilloma virus (HPV) using PCR and Southern analysis. Those tumours 
identified as having an increased probability of harbouring a mutation, were then 
subjected to further analysis by PCR-single strand conformational polymorphism 
(SSCP), a technique which relies on conformational differences between normal and 
mutant single strand DNA to detect mutations. 
The results revealed that only 2 out of 53 informative tumours demonstrated LOH of 
the p53 gene. Both these tumours were HPV negative. Using PCR-SSCP no evidence 
of mutations in exons 5 to 8 was detected in either of these tumours, or in any of 1_6 
other HPV negative tumours examined. These results are in agreement with the low 
incidence of p53 mutations in cervical tumours of other populations reported in the 
literature. They also support the hypothesis that HPV E6 inactivation of the p53 
protein is the predominant contributory factor to carcinogenesis of the cervix and that 
p53 mutations are more frequently involved in the absence of HPV infection. 
Since no mutations were detected by PCR-SSCP in exons 5 to 8, it is possible that 
mutations could be present in other exons. These exons were subsequently analysed 
by Dr Tim Crook of the Rayne Institute, Kings College School of Medicine, London 
who reported SSCP band mobility in exons 2/3 in both cervical tumours which showed 
LOH. 
These findings suggest firstly, that LOH as determined by the technique described in 
this study is a useful primary screen for mutations in the p53 gene and secondly, that 
Black South African women may have a novel pattern of p53 mutations in carcinoma 
of the cervix. 
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1.1 GENETIC ASPECTS OF MALIGNANCY 
Cancer is essentially a disorder of cellular growth. It often manifests as a mass of cells, 
the visible tumour being the end result of a sequence of events known as 
carcinogenesis. This is a complex multistep process which is believed to involve initial 
changes at the genetic level; these changes can be either congenital or acquired 
(Cotran et al, 1989). 
In normal cells cellular proliferation is under the control of both growth-promoting 
and growth-suppressing genes (Goldberg et al, 1991). This genetic control can be lost, 
for example, by damage to the DNA which the cell's repair mechanisms fail to correct. 
Thus alterations in growth-promoting genes may result in the stimulation of tumour 
cell growth. On the other hand, genetic defects that inactivate growth-suppressing 
genes liberate the cell from the constraints imposed by these genes, and thereby may 
also contribute to the carcinogenic process. 
In recent years the application of molecular biological techniques to the study of 
various human cancers has demonstrated that defects in a relatively small number of 
genes occur repeatedly in tumours. A deeper understanding of these genes, as well as 
the various types of genetic alterations that occur and their frequency and distribution, 
may lead to an elucidation of the aetiology and prevention of malignant tumours. 
Furthermore this knowledge may aid in the diagnosis and monitoring of cancer and 
in the future may lead to advances in therapy (Goldberg et al, 1991; Lee, 1991; Harris, 
1993; Roth, 1993). 
CARCINOGENESIS AS A MULTISTEP PROCESS 
The development of a carcinoma is generally believed to occur following a complex 
succession of changes in a particular cell population. This process is far from clearly 
understood, and there is no single model that explains the development and aberrant 
growth of all tumours. 
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The changes that occur in the transformation of normal cells to malignant cells involve 
several factors such as loss of regulated growth, dedifferentiation and synthesis of 
abnormal proteins. The process of carcinogenesis also involves several secondary 
events such as angiogenesis and metastasis. All these changes are now thought to be 
initiated at the genetic level (Craft and Harris, 1994). 
Early studies on mouse skin showed that tumour development can be induced 
following exposure to various agents termed initiators and promoters (Berenblum and 
Shubik, 1947). In these experiments a single, low dose of initiating agent produced no 
tumours during the life span of the animal. However when the low dose of initiating 
agent was followed by repetitive doses of a promoting agent, high yields of papillomas 
and ultimately carcinomas were obtained. No tumours developed when only the 
promoting agent was applied or when the promoting agent was applied before the 
initiating agent. Among the initiators are various chemical and physical agents such as, 
hydrocarbons, viruses, ionizing radiation and UV light, and among the promoters are 
hormones and normal growth promoters (Franks, 1991). Chemicals that initiate 
carcinogenesis are extremely diverse in structure, but they all fall into one of two 
categories; direct-acting compounds, which do not require chemical transformation for 
their carcinogenic effect, and indirect-acting compounds which require metabolic 
conversion to produce carcinogens capable of transforming cells. Both types of 
chemical carcinogens form covalent adducts (addition products), are highly reactive 
and may attack several electron rich sites in the target cells, including DNA, RNA and 
proteins, sometimes resulting in lethal damage (Cotran et al, 1989). 
The steps in the development of neoplasia are now attributed to defects or mutations 
commonly occurring in a class of genes broadly described as oncogenes (these are 
discussed fully in Section iii). All known oncogenes are involved to some degree in 
growth regulation and several oncogenes are now known to act in collaboration with 
one another in tumorigenic transformation. For example, oncogene products acting in 
the nucleus co-operate with those that act in the cytoplasm to transform normal cells 
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into tumour cells. This strongly suggests that each oncogene makes a unique 
contribution to the process of carcinogenesis. This is clearly illustrated in a recent 
model proposed by Fearon and Vogelstein (1990) for human colon cancer (Fig 1.1), 
which shows how discrete genetic changes correlate with specific steps in tumour 
development. The changes have been statistically associated with each step in tumour 
progression, and although individual tumours may take a slightly different path to the 
endpoint, the model demonstrates that tumour formation is the consequence of a 
series of genetic changes. The precise factors influencing these changes are still to be 
clearly elucidated. Although this model has been proposed for a specific tumour type, 
it is likely that most tumours arise following a similar sequence of genetic alterations, 
which may be the result of inherited, socioeconomic or enviromental factors. 
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Fig 1.1. Genetic changes occuning during evolution of a typical colon carcinoma (reproduced from Fearon 
and Voge/stein, 1990). 
ii INHERITED AND SPORADIC CANCERS 
As alluded to previously, almost all types of tumours occur in both a familial and a 
sporadic form. In the rarer familial form which accounts for less than 5% of all 
cancers, the tumour itself is not inherited, but rather the genetic susceptibility to 
develop cancer. 
Studies carried out by Knudson (1971) in both the inherited and sporadic forms of the 
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childhood malignancy retinoblastoma (Rb), gave rise to the 'two hit' hypothesis in 
which he proposed that at least two mutations are necessary for tumour formation. 
Knudson suggested that in the inherited form a mutation is carried in the germ line. 
For the disease to manifest itself, however, a second somatic mutation must 
subsequently occur in the other allele. On the other hand, in the sporadic form of the 
disease, mutations in both alleles appear to occur in somatic tissue. 
Following these observations Knudson proposed a class of genes in which the mutated 
gene is recessive because both copies of the gene must be defective before the tumour 
manifests itself clinically. However upon investigation, in some instances no specific 
second mutation was detected, but rather a complete loss of the corresponding allele. 
These findings suggested that the complete absence of any normal gene product is a 
prerequisite for tumour formation and hence the name tumour suppressor gene was 
adopted. It is now believed that most inherited cancers involve genes which fall into 
this category. 
iii ONCOGENES AND TUMOUR SUPPRESSOR GENES 
At the beginning of this review it was mentioned that the development of neoplasia 
is attributed to alterations in a relatively small number of genes, all of which are 
involved in some way in the function of normal cellular growth (Lane, 1991). These 
genes are divided into two major categories: oncogenes (proto-oncogenes) which act 
in a dominant gain-of-function fashion to promote tumour growth, and tumour 
suppressor genes which act in a recessive loss-of-function manner. 
a Oncogenes/proto-oncogenes 
Oncogenes are normal regulatory genes which have undergone a mutation and 
consequently may contribute to tumorigenesis. Prior to a mutation they are 
known as proto-oncogenes. It would appear that a single mutation is sufficient 
to cause activation, the mutated gene acting as dominant to the wild-type allele 
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(non-mutated or normal allele). The dominant nature of oncogene mutations 
does not permit these mutations to be inherited through the germ line, since 
their expression in the fetus is likely to disrupt development and be lethal 
(Levine, 1993). A recent report however, indicates that this may not always be 
true for all oncogenes; a unique clearly inherited mutation in the ret proto­
oncogene has been identified in 48 of 50 patients from 34 families with MEN 
(multiple endocrine neoplasia) type 2 (Lips et al, 1994 ). 
Oncogenes/proto-oncogenes comprises a group of genes whose products can 
be divided into 5 different classes of molecules according to their function and 






growth factors eg. fibroblast growth factor related (int-2), platelet­
derived growth factor related (sis). 
growth factor receptors eg. truncated epidermal growth factor receptor 
(erb-B), mutant colony-stimulating factor receptor (fins). 
protein kinases eg. nonreceptor protein-tyrosine kinase (src), truncated 
receptor-like protein-tyrosine kinase (ret). 
nuclear DNA-binding proteins or transcription factors eg. sequence­
specific DNA-binding protein (myc), thyroid hormone receptor (erb A). 
G proteins eg. membrane-associated GTP-binding/GTPase (K-ras, N­
ras), mutant-activated form of G
5 
(gsp). 
All these genes form part of signal transduction pathways or serve as part of 
the intracellular regulatory machinery, or both. 
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b Tumour suppressor genes 
These are normal growth regulatory genes which can undergo mutation to 
result in a loss of regulatory properties. Mutations in tumour suppressor genes 
generally cause a loss of function but act as recessive to the wild-type. This 
means that these genes require two independent mutations to manifest a loss 
of growth regulatory properties. It would appear that this most commonly arises 
by a mutation in one allele associated with a loss of part, or the whole of the 
corresponding allele. This phenomenon is known as loss of heterozygosity 
(LOH), loss of allele or reduction to homozygosity (Levine, 1992). 
There are however several ways in which the normal allele can be inactivated. 
These include chromosome loss, chromosome duplication, translocation, 
deletions, point mutations, as illustrated in Figure 1.2. 
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Fig 1.2. Examples of different ways i11 which a 11omial allele can be inactivated. 
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iv TYPES OF GENETIC ALTERATIONS 
Several different types of genetic alterations can occur in malignancy. These include: 
a Point mutations 
This is a single base change in a specific codon which results in an amino acid 
su bsti tu tion. 




Silent mutations within a gene - these occur if a point mutation takes 
place at the third nucleotide position of a codon, and changes the codon 
but not the amino acid. 
Missense - this is a change in a codon which results in a new amino 
acid. 
Nonsense - this is a change of an amino acid codon into a termination 
codon, resulting in a truncated protein. 
b Insertion/deletion 
This is the addition or deletion of genetic material ranging from one base to 
large pieces of DNA. An insertion or deletion of a number of bases not 
divisible by three is known as a frameshift. Such mutations usually result in the 
generation of termination codons. 
c Trans location 
This is a rearrangement of a chromosome in which a segment is moved from 
one location to another, either within the same chromosome or to another 
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chromosome. It can also be reciprocal when one fragment is exchanged for 
another. 
d Gene amplification 
This is selective replication of a DNA sequence resulting in multiple copies of 
that sequence or gene. 
e Viral activation 
Several direct mechanisms of viral activation exist and include: 
*
* 
Retroviral transduction - retroviruses contain transforming genes that
are capable of inducing tumours. These viral oncogenes (v-onc) are
mutated versions of their cellular counterparts ( c-onc) (Sleeman, 1992).
Retroviral insertion - many retroviruses do not contain oncogene 
sequences but initiate tumorigenesis by inserting viral DNA, which has 
been copied from the viral RNA by the enzyme reverse transcriptase 
into the host genome. This may alter the expression of the adjacent 
cellular genes, leading to point mutations, amplifications, truncations or 
hybrid transcripts with aberrant coding sequences (Sleeman, 1992). 
Other mechanisms of viral involvement are not direct but are based on the 
interactions of viral oncoproteins with the proteins produced by tumour 
suppressor genes, for example, the interaction of the E7 oncoprotein of the 
human papilloma virus (HPV) with the product of the Rb gene (Lee, 1991). 
This is discussed in more detail in Section 1.3. 
f Methylation 
DNA methylation is the transfer of methyl groups to cytosine residues on the 
cytosine-guanine doublet (CpG) by an enzyme called cytosine DNA methyl 
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transferase (DNA-MTase) to form 5-methylcytosine. This process is known to 
play a role in the regulation of gene activity (Goodman and Counts, 1993) by 
providing a chemical signal that is recognised by transcriptional regulation 
factors. 
In normal cells, the function of DNA methylation may be to ensure that areas 
of transcriptionally active chromatin replicate earlier than the transcriptionally 
inactive chromatin. Thus any alteration in DNA-MTase may create changes in 
the methylation status and alter the expression of the gene. Global DNA 
hypomethylation has been observed in some human neoplasms and has been 
implicated as an important factor in carcinogenesis (Kim et al, 1994). 
v GENETIC ALTERATIONS IN SPECIFIC CANCERS 
A number of cancers both familial and sporadic, have been shown to have specific 
aberrations. Amongst the familial forms are: alterations on a gene located on 
chromosome llp13 producing Wilm's tumour of the kidney which occurs in infants and 
young children (Lee, 1991). Mutations on a gene located on the long arm of 
chromosome 17 are responsible for neurofibromatosis type 1 (NFI), which is associated 
with an increase risk of malignancies, principally neurofibrosarcoma and optic glioma 
(Vile, 1992). Alterations on a gene known as APC located on chromosome 5 
commonly occur in familial adenomatous polyposis, a disorder in which affected 
individuals develop multiple colonic and rectal polyps. Alterations in loci mapped to 
the long arm of chromosome 11 and to the pericentromeric region of chromosome 10 
produce respectively, multiple endocrine neoplasia types 1 and 2 A: this disease includes 
disorders with hyperfunction of two or more endocrine tissues. Alterations on the p53 
gene, which is located on the short arm of chromosome 17 are responsible for a rare 
familial cancer called Li-Fraumeni syndrome characterized by the occurrence of diverse 
mesenchymal and epithelial neoplasms at multiple sites. The spectrum of cancers in 
this syndrome include breast carcinomas, soft tissue sarcomas, brain tumours, 
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osteosarcomas, leukemia, adrenocortical carcinoma, and possibly other tumours types 
such as melanoma (Lee, 1991). Alterations on two genes namely, BRCAl and BRCA2 
located on chromosome 17q21 and 13q12, respectively, are reported to be involved in 
familial breast cancers (Futreal et al, 1994; Miki et al, 1994; Wooster et al, 1994). 
Sporadic cancers are also linked to specific mutations. Although defects in the p53 
tumour suppressor gene are reported to be the most commonly occurring genetic 
abnormality in all cancers in general, clearly differing frequencies of p53 involvement 
are observed in different tumour types. For example, the frequency of mutations of the 
p53 gene is reported to be 33% in breast carcinomas (Sommer et al, 1992), 61 % in 
hepatocellular carcinomas (Hsia et al, 1992) and 72% in ovarian carcinomas (Kohler 
et al, 1993). 
Amplification of the neu (also called c-erbB-2 or HER-2) proto-oncogene is reported 
in approximately 20% of all breast tumours and some ovarian tumours but is not 
widely observed in other malignancies. Similarly, amplification of the mdm-2 (murine 
double minute) oncogene on chromosome 12q is reported in approximately 30% of all 
soft tissue sarcomas (Harris and Hollstein, 1993). 
Translocations are common occurrences in certain types of leukaemias and lymphomas 
such as the t(9:22) crossover which results in the generation of the Philadelphia fusion 
gene (Russell, 1992). Several other examples exist, such as, the t(S:21) crossover in 
acute myeloid leukaemia (AML), the t(4:11) in acute lymphoblastic leukaemia (ALL) 
(Hoffbrand and Pettit, 1994) and the t(8: 14) in Burkitt's lymphoma (Wolfe, 1993). 
Translocations are also frequent in soft tissue sarcomas (Sreekantaiah et al, 1994 ). 
vi POSSIBLE CLINICAL USEFULNESS 
The knowledge of the precise defects that occur in different tumours holds potential 
for future intervention in several ways: 
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a Aetiology 
Studies on cancer-related genes have revealed some of the possible 
environmental and endogenous molecular processes that may lead to 
carcinogenesis. For example, specific p53 mutations at codon 249 in 
hepatocellular carcinoma, commonly occur in patients residing in high-risk 
regions of the world ( China, Mozambique) where there is high intake of dietary 
aflatoxin Bl and increased risk of infection with the hepatitis B virus (Hsu et 
al, 1991; Hsia et al, 1992). Information of this type might be useful in 
prevention. 
b Diagnosis 
Studies of some genes, particularly those involved in haematological tumours 
are being used to aid diagnosis, monitor response to therapy and detect 
minimal residual disease. Examples include the t(9:22) translocation in CML 
( chronic myelogenous leukaemia) and the t( 4: 11) translocation in ALL (Russell, 
1992). In cancer of the breast, c-erbB2 amplification has been associated with 
more aggressive tumour growth and is now being used to identify subgroups of 
patients with a particularly poor prognosis (Russell, 1992; Knyazev et al, 1993; 
Muss et al, 1994). 
In familial cancers detection of germline mutations has obvious uses in prenatal 
diagnosis and counselling and in the identification of individuals at risk 
(Malkin, 1994; Russell, 1992). 
c Future developments 
The frequent failure of currently available cancer therapies is largely 
attributable to two characteristics of human malignancies; tumour cell 
heterogeneity and genetic instability of the malignant clone. Combination 
therapies targeted to the various steps in the transformation process of 
carcinogenesis may be invaluable. 
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There are several possible approaches to therapy, for example antisense 
oligonucleotides targeted to mRNA, proteins as targets for specifically designed 
antibodies, and corrective gene therapy (Roth, 1993; Tari and Lopez­
Berestein, 1993). 
1.2 THE p53 TUMOUR SUPPRESSOR GENE 
The p53 tumour suppressor gene is one of the main foci of this thesis and will 
therefore be reviewed in detail here. 
i HISTORY 
Mutations in the p53 gene are reported to be the most common genetic alteration in 
human cancers. Yet until recently, little was known about the functions of the p53 
gene product. 
The nuclear p53 protein was originally reported to form a complex with the simian 
virus 40 (SV40) oncoprotein, the large T antigen, in cells infected by this virus. 
Because large T antigen is needed to maintain the transformed cells, it was suggested 
that this interaction was important for transformation. The p53 protein was therefore 
described as a tumour antigen (Eliyahu et al, 1984). 
The gene encoding p53 was later shown to transform rodent cells in vitro, either alone 
or in co-operation with an activated ras gene (Eliyahu et al, 1984; Lamb and 
Crawford, 1986). These transfection experiments, together with the demonstration that 
p53 gene expression was increased in a variety of chemically, virally and genetically 
transformed human and rodent tumour cells (Nigro et al, 1989) suggested that the p53 
gene was an oncogene that could exert its growth-promoting effects if expressed at 
high level. At this point the p53 gene was classified as an oncogene. 
A review of the literature 13 
However subsequent attempts to repeat these experiments were unsuccessful and it 
was realized that the early transformation studies were performed with a mutated form 
of the p53 gene. Further studies showed that the normal p53 gene behaves as a tumour 
suppressor gene, regulating the cell cycle and requiring to become mutated in order 
to lose these regulatory properties. At the same time mutations and deletions of 
various p53 alleles in several human tumours were reported (Levine et al, 1991). Thus 
convergent lines of research indicated that the wild-type (normal) p53 gene functions 
as a tumour suppressor gene and today it is recognised as such. 
ii STRUCTURE 
The p53 gene comprises 20 kb of DNA and is located on the short arm of human 
chromosome 17, at position 17p 13.1. The gene contains 11 exons, the first of which 
(213 bases) is noncoding. A notable feature is that intron 1 is 10 kb long, which is 
approximately 50% of the entire gene (Lamb and Crawford, 1986). Little is known 
about the nucleotide sequences regulating the transcription of this gene. The mRNA 
for p53 is expressed in all cells of the body with the highest levels being found in the 
spleen and thymus (Levine, 1993). 
iii p53 PROTEIN 
The protein encoded by the p53 gene comprises 393 amino acids in humans and is a 
nuclear phosphoprotein. The protein is composed of three functional domains: an 
alpha-helical stretch of 75 amino acids at the amino-terminal end, followed by a 
hydrophobic region rich in proline residues ( codons 75-150) and finally, at the carboxy­
terrninal end of the protein (codons 319-393), a basic region of alpha helix 
conformation. The regions of the protein that frequently carry activating mutations are 
spread through the protein in certain 'hot-spots'. These are at codons 111-136, 165-175, 
230-252 and 264-280. The functional significance of these areas of the protein is not
fully described but they show a high degree of conservation between p53 proteins of 
different species (Levine, 1993). 
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iv FUNCTION 
The p53 protein exerts its growth regulatory properties in several ways: 
a Cell cycle arrest 
Studies have shown that the wild type p53 protein introduced directly into 
tumour cells arrests growth of the tumour cells in the late Gl phase of the cell 
cycle. This allows the cell sufficient time to repair damage. The role of p53 is 
therefore, postulated as a monitoring protein that determines whether the cell 
enters the S phase to continue through the cell cycle. It is reported to be 
synthesised in response to DNA damage, and has important implications in the 
maintenance of the cell's genetic stability (Donehower, 1994). 
b Transcriptional regulation 
The p53 protein binds to specific DNA sequences to act as a transcription 
factor in regulating the expression of particular genes which include the p21 
and GADD45 (growth-arrest-and-DNA-damage inducible) genes. The p53 
protein may halt DNA synthesis through p21 allowing time for the damage to 
be repaired. It would appear that p53 can also stimulate the repair mechanism 
through the GADD45 gene which is found in cells exposed to stress 
(Marx, 1994). 
c Apoptosis 
Apoptosis, or programmed cell death, was first described in the 1970s 
(Lane, 1993). Cells that do not have the ability to undergo apoptosis continue 
to grow uncontrolledly. Furthermore, defects in genes that regulate this event 
hold a double threat for the cell: as well as the absence of normal cell death, 
they can also confer tolerance to chemotherapy and radiotherapy. 
A number of experiments support a role for p53 in apoptosis. It has been 
demonstrated that wild-type p53 mediates apoptosis of both normal and tumour 
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cells. This is possibly a defence mechanism to protect the organism against cells 
that have undergone transformation (Cohen, 1993). 
Other evidence for the role of p53 in apoptosis was obtained following ionizing 
radiation experiments, in which cells from mice containing wild-type p53 
entered apoptosis after treatment with ionizing radiation (Lane, 1993). By 
contrast, cells with two defective p53 alleles did not undergo apoptosis 
following similar treatment (Donehower, 1994 ). It would also appear that DNA 
damage that is incapable of being properly repaired may induce a p53-mediated 
apoptosis program and has led to the concept that p53 might be part of a 
damage-control pathway in addition to a normal-control pathway (Lane, 1993). 
Further studies suggest that p53 may also induce apoptosis in response to an 
imbalance in growth signals. For example, if positive growth signals are 
activated through c-myc oncoprotein deregulation in the absence of appropriate 
growth factors, negative growth regulators such as p53 may detect the resulting 
imbalance, and induce an apoptotic pathway (Lane, 1993). 
v DETECTION OF p53 MUTATIONS 
A large variety of human tumours are reported to contain a mutated p53 tumour 
suppressor gene. The majority of these mutations are found in 4 highly conserved 
regions of exons 5 to 8 (Hollstein et al, 1991). 
Several different methods of detection have been developed. The definitive method 
is direct nucleic acid sequencing, but this can be laborious and expensive when large 
number of samples are involved, even with the use of an automatic sequencer. There 
are however several indirect methods which can be used as screening techniques. 
Amongst these are: 
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a The detection of loss of heterozygosity (LOH) 
As mentioned previously (Section 1.1 iii), mutations in tumour suppressor genes 
are commonly associated with the loss of the corresponding allele. This loss is 
apparently necessary for carcinogenesis, reflecting the recessive nature of these 
genes. About 80% of mutations in the p53 gene are thought to be associated 
with LOH. Thus this technique is a useful means of screening for mutations in 
the p53 gene. 
To detect loss of heterozygosity paired samples of DNA from blood and tumour 
are compared to identify loss of allele in the tumour DNA. The methodology 
is described fully in Chapter 3. 
b Single strand conformational polymorphism (SSCP) 
This technique relies upon the fact that, under non-denaturing conditions, 
single-strand DNA molecules carrying mutations fold into unique conformations 
(Hongyo et al, 1993), which under appropriate electrophoretic conditions 
migrate differently to wild-type DNA. This technique is described in 
Chapter 5. 
c Heteroduplex analysis (HA) 
This method is based upon the observation that a hybrid between two single­
stranded DNA molecules with sequences which differ from each other by a 
single nucleotide (heteroduplex), has an altered conformation. This may be 
detected as a reduction in electrophoretic mobility on a denaturing gel 
(Ganguly et al, 1993). 
Several other methods exist for the detection of mutations, such as restriction site 
analysis, band shift assay, the use of allele-specific oligonucleotide primers and probes. 
To make use of these techniques however, the precise location and nature of the 
mutation must be known. 
A review of the literature 17 
vi RELATIONSHIP OF p53 TO VIRAL ONCOPROTEINS 
The p53 protein has been shown to interact with several viral oncoproteins including 
the SV40 large T antigen, the ElA adenovirus and the E6 protein product of the HPV 
types 16 and 18 (Levine, 1993). As discussed previously (Section 1.2 i), the inactivation 
of a normal suppressor gene protein by complexing with viral oncoproteins is believed 
to play an indirect role in carcinogenesis of certain tumours, particularly those of the 
uterine cervix. This relationship between the p53 gene and its product, the HPV and 
cancer of the cervix is discussed in greater detail in the following section. 
1.3 CANCER OF THE CERVIX AND HUMAN PAPILLOMA VIRUSES 
There is overwhelming evidence that human papillomaviruses are involved in the 
aetiology of cervical cancers, with HPV DNA being reported in approximately 70 to 
90% of all cervical tumours (Levine, 1992; Jha, 1993). 
Furthermore it is recognised that HPV infection of the cervix, specifically the HPV 16 
and 18 types, progresses to malignancy in a significant number of patients. It was 
estimated following a study of 530 women from Finland, that 80% of women with 
HPV 16 infection finally progressed to malignancy (Jenkins, 1994). 
The nature of this relationship between HPV and cancer of the cervix has been better 
understood recently with the demonstration that the E6 oncoprotein product of the 
HPV 16 and 18 types binds to wild type p53 protein (Scheffner et al, 1990). The 
complex formed results in an altered half life of the p53 protein (Band et al, 1993) and 
in addition, targets the p53 protein for attack by proteolytic enzymes (Scheffner 
et al, 1990). The result is the functional inactivation of the p53 tumour suppressor 
protein. As a consequence, it has been hypothesized that cervical tumours which 
contain HPV 16 and 18 DNA are less likely to have mutations in the p53 tumour 
suppressor gene (Scheffner et al, 1990). 
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This concept has been supported by cell line studies, in which mutant forms of the p53 
gene were found only in those cervical cells without HPV DNA. Investigations carried 
out by Crook et al (1992) and Scheffner et al (1991) revealed that two cervical 
carcinoma cell lines, C33a and HT3, in which HPV DNA was not detected, contained 
mutations in codon 273 and codon 245 respectively. These studies were confirmed by 
Iwasaka et al (1993). 
It may be that in tumours of the cervix, allele loss and/or mutations in the p53 gene 
are a rare event, and have little role in the carcinogenic process, in contrast to other 
malignancies. This hypothesis has been addressed by a handful of researchers (Crook 
et al, 1992; Kaelbling et al, 1992; Busby-Earle et al, 1993; Paquette et al, 1993). For 
example, Crook and his associates, analysed tumour tissue samples from 28 women 
with primary cervical tumours for the presence of HPV sequences and for somatic 
mutations of the p53 gene. Twenty five of the tumours contained HPV sequences 
without any evidence of p53 mutation. Point mutations were detected in the remaining 
three HPV negative tumours. Similarly Paquette et al (1994) undertook a study of 42 
cervical carcinomas, 42 of which were HPV positive with normal p53. A missense 
mutation was detected in one of the three HPV negative tumours. Kaelbling 
et al (1992) analysed 27 cervical carcinomas for the presence of HPV and showed that 
21 had HPV infection. LOH of the p53 gene was found in 4 of the 27 cases, two of 
which had no evidence of HPV. 
To date there would appear to be a degree of consensus concerning the likelihood that 
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p53 mutations are not common in carcinoma of the cervix. However, these findings are 
based on very small numbers of patients and therefore require confirmation. 
Furthermore, the complete absence of information on the p53 gene in populations 
groups known to be at high risk for cancer of the cervix, such as Black women of 
Southern Africa (Cooper et al, 1991), suggests that further studies are essential. 
1.4 INTRODUCTION TO THE PRESENT STUDY 
This review of the literature on the genetic aspects of malignancy has revealed several 
salient features. Firstly, the p53 tumour suppressor gene appears to be of major 
significance in the maintenance of normal cellular growth and control. There have 
been numerous reports of genetic alterations of the p53 gene in a large variety of 
human tumours including those of the colon, rectum, lung, breast, brain, bone, and 
bladder. 
The second point to emerge from the review, was the fact that while p53 involvement 
has been extensively studied in some tumours, others, more specifically tumours of the 
uterine cervix have been largely overlooked. The high prevalence of this cancer in the 
Black South African population makes this malignancy a particular focus of interest. 
Thirdly, it would appear that with the exception of one study reporting variations in 
p53 mutations in a cohort of Black Americans with breast cancer (Blaszyk et al, 1994), 
no studies on the p53 gene have been carried out in racial groups other than whites 
and Japanese. 
Given these three factors, a study was undertaken on the prevalence of p53 
abnormalities in carcinoma of the cervix amongst Black South African women. At the 
same time an analysis was made of the HPV status and the specific type identification 
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of HPV present in the tumours in the study group. 
The study was approached in the following way: 
a Examination of tumour and blood DNA for loss of heterozygosity of the 
p53 gene as a primary screen for mutations. 
b Examination of the tumours for HPV 16 and 18 types. 
c Analysis by PCR-SSCP of DNA from tumours showing LOH as well as 
HPV negative tumours as a secondary screen for mutations. 
d Evaluation of all results to assess the relative contribution of p53 
mutations and HPV infection to cervical carcinogenesis. 
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2.1 INTRODUCTION 
The purpose of this chapter is to describe the principles and practical details of the 
molecular biological techniques used in this study. Specific details of the more complex 
methodologies such as the polymerase chain reaction (PCR) and single strand 
conformational polymorphism (SSCP) are described in the relevant chapters. 
2.2 CLINICAL SAMPLES 
i COLLECTION AND STORAGE 
Tumour tissue was collected at surgery. Samples were placed on ice for transport to 
the laboratory, and then stored in liquid nitrogen (-196°C) until isolation of DNA Al  
tumour samples were histologically confirmed on routine analysis. 
Blood was collected into tubes containing EDTA in the post-operative period and 
stored as whole blood at -20°C. 
ii ETHICAL PERMISSION 
Al  specimens were obtained in compliance with the Ethics Committee of the Faculty 
of Medicine of the University of Natal. Verbal consent for the use of samples for 
analysis was obtained from patients. 
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2.3 LABORATORY METHODS 
i ISOLATION OF DNA 
There are several methods available for the extraction of DNA from a variety of 
sources. The choice of method is dependent largely on the nature of the source, and 
on the use to which the DNA is to be put. When DNA of high purity is required, as 
in the case of cloning procedures, the classical phenol/chloroform extraction method 
is recommended (Sambrook et al, 1989b ). However other procedures, for example 
PCR, do not require very pure DNA, reducing the need for extensive purification. In 
some cases a rapid alkaline boiling method can be used (Williamson B, personal 
communication). 
Principle 
The DNA isolation procedure chosen for this study is a modification of a salting out 
procedure (Miller et al, 1988) which involves the use of a strong salt solution such as 
6 mol/1 NaCl. The technique is based on the fact that DNA, unlike proteins, is soluble 
in high concentrations of salt. The cell homogenate is suspended in this solution, the 
proteins removed by centrifugation and DNA is recovered from the supernatant. This 
method was selected because with appropriate modifications it can be used to isolate 
nucleic acids from different sources. In addition it yields DNA which can be used for 
both PCR amplification and hybridisation techniques. 
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Procedure 
Extraction of DNA from tumour tissue 
Proteinase K was used to deproteinise tumour tissue homogenates. The steps involved 
in this extraction procedure were: 
a Frozen tumour tissue (approximately 100 mg) was finely cut with a razor blade 
and lysed with RNAse (15 µg/ml), proteinase K (15 µg/ml) and 10% SDS for 
24 h at 37°C, or 5 h at 65°C. The tubes were shaken from time to time, until 
all the tissue was disrupted. 
b 6 mol/1 NaCl was added to the tissue digest to a final concentration of 1 mol/1 
and shaken gently for 10 min at 24°C. 
c The mixture was centrifuged at 2500 g for 15 min at 24 °C to remove the 
proteins. 
d The supernatant was extracted with a 1: 1 volume of chloroform-isoamylalcohol, 
and centrifuged at 2000 g for 15 min at 4 °C. 
e The supernatant was transferred to a glass tube and the DNA precipitated 
using isopropanol in a proportion of 1: 1. 
f The DNA strands were removed using a bent Pasteur pipette, washed in 70% 
ethanol and redissolved in TE buffer. The buffer comprises 10 mmol/1 Tris­
HCI; 1 mmol/1 EDTA (pH 8). 
g The concentration of DNA was determined (see Section 2.3 ii), and aliquots 
were stored at either -20°C or -70°C. Storage at -70°C, especially for longer 
periods was preferred because it avoided the possibility of pockets of unfrozen 
liquid of high salt concentration which can damage the DNA. 
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Extraction of DNA from whole blood 
The extraction of DNA from blood was carried out as follows: 
a Equal volumes of fresh blood and solution A (6 g dextran 170 in 0.9% NaCl 
and 200µ1 of 0.5 mol/l EDTA per 10 ml of blood) were added to narrow plastic 
or glass tubes. These were left to stand at an angle of 45° for 1 h at ambient 
temperature or 20 min at 37°C. 
b Frozen blood was thawed at 37°C and diluted with an equal volume of 
0.9% NaCl. 
c The blood (fresh or frozen) mixture was washed twice with 0.9% NaCl by 
centrifugation at 3500 g at 4 °C for 15 min. 
d The white cell pellet was then resuspended in 2 ml 0.9% NaCl, 2 ml 0.5 mol/1 
EDTA (pH 8) and 880 µI mol/1 NaCIO
4 
and mixed well. 
e To this was added 0.4 ml of 10% SOS and mixed gently. The solution of lysed 
cells was left to stand for 10 min. 
f Five ml of a 24:1 chloroform-isoamylalcohol mix was added. The two phases 
were mixed by shaking slowly for 15 min; if the phases did not form an 
emulsion, the tubes were shaken mechanically for 1 h. 
g The two phases were separated by centrifugation at 5000 g for 10 min at 4° C. 
h The viscous aqueous phase containing the DNA was transferred to a 
polypropylene tube, and the extraction repeated with 5 ml of chloroform. 
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The DNA solution was centrifuged at 5000 g for 15 min at 4 ° C to precipitate 
the proteins. The supernatant was transferred to a glass tube, and DNA 
precipitated by adding 1:1 isopropanol. 
J The DNA was washed using 70% ethanol and redissolved in TE buffer. 
k The DNA concentration was determined (Section 2.3 ii) and aliquots stored 
at -20°C or -70°C. 
ii MEASUREMENT OF DNA 
Principle 
The UV absorbance peaks of nucleic acids and proteins are at 260 nm and 280 nm, 
respectively; the absorbance at 260 nm reflects the concentration of nucleic acid in the 
sample, while the absorbance at 280 nm the amount of protein present in the DNA 
solution. A ratio of these two readings gives an estimate of the amount of impurities, 
a ratio greater than 1.8 generally being considered acceptable (Wenham, 1992). 
It is estimated that double stranded DNA at a concentration of 50 µg/ml and single 
stranded DNA at a concentration of 33 µg/ml each have an OD of 1. These values are 
used to calculate the concentration of DNA in any solution (Sambrook et al, 1989). 
Procedure 
The absorbance of a diluted solution of DNA (usually 1: 100) was measured in a 
Beckman DU
®
-5 spectrophotometer (Beckman Instruments Inc, Fullerton, California) 
at the wavelengths 260 nm and 280 nm. The ratio of these two readings was calculated 
and the concentration of DNA estimated as follows: 
A
260 
x 50 µg/ml DNA x dilution factor. 
The final concentration was expressed as µg/ µl. 
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iii SEPARATION AND DETECTION OF DNA 
It is frequently necessary to separate and detect different DNA fragments, either for 
identification or isolation. This is generally performed using electrophoretic techniques. 
Two common supports are used, namely agarose and polyacrylamide, and are selected 
on the basis of the size of the DNA fragment to be detected and the resolution 
required. 
a Agarose gel electrophoresis 
Principle 
At neutral pH, DNA is negatively charged and in the presence of an electrical 
current, DNA loaded into a well at the cathode end of a gel moves through the 
gel towards the anode. The electrophoretic mobility of DNA fragments in 
agarose is dependent on fragment size and is fairly independent of base 
composition or sequence. The resolving power of an agarose gel is a function 
of its concentration (Sambrook et al, 1989e), with the concentration being 
inversely proportional to the size of the DNA fragment to be detected. 
Procedure 
Electrophoresis was carried out using the Hoefer Mighty Small (Hoefer 
Scientific Instruments, San Francisco, California) horizontal apparatus. The 
running buffer was a Tris-borate (TBE) buffer made up as a 5 x concentrated 
stock solution and diluted to a 0.5 x working solution. The 5 x TBE buffer was 
prepared as follows: 0.4 mol/1 Tris; 0.4 mol/l boric acid; 1 mrnol/1 EDTA (pH 
8). The loading buffer was 2 g Ficoll; 3.2 ml 0.5 mol/1 EDTA (pH 8); 20 mg 
bromophenol blue; made up to 8 ml in 0.5 x TBE. 
The gel was cast by melting the appropriate amount of agarose in TBE buffer 
(in a microwave oven) until a transparent solution was obtained. The melted 
Materials and methods 28 
solution was first cooled to approximately 50
°
C, to prevent damaging the gel 
tray, then poured into a mould and allowed to set for approximately 30-45 min. 
After removal of the comb, the gel submerged in running buffer was loaded 
with the required amount of DNA preparation or PCR product mixed with 
2 µl loading buffer. The Ficoll in this buffer makes the DNA solution more 
dense so that it sinks to the bottom of the well, and the bromophenol blue is 
used as a tracking dye. In addition, an appropriate molecular weight marker 
was included in every run. The gel was run at a constant voltage of 8 V /cm at 
room temperature until the dye front reached the bottom of the gel. After 
electrophoresis the gel was viewed and documented as described below. 
Staining and imaging of the gel 
The most convenient method to visualise DNA in an agarose gel is staining 
with the fluorescent dye ethidium bromide. This substance intercalates between 
the bases, binding to DNA and this is visualized as a fluorescent band under 
ultraviolet radiation (Sambrook et al, 1989e). 
Ethidium bromide was prepared as a stock solution of 10 mg/ml in water, and 
kept in bottles wrapped in aluminium foil in a fume cupboard at room 
temperature. After electrophoresis was completed, the gel was immersed in 
water containing ethidium bromide (0.5 µg/ml) for 30-45 min at room 
temperature. The gel was destained by soaking in water for 10 min at room 
temperature; this reduced the excess of background fluorescence caused by 
unbound ethidium bromide. 
Alternatively the dye was incorporated into the gel and/or the electrophoresis 
buffer at a concentration of 0.5 µg/ml. This allowed examination of the gel 
directly under ultraviolet light during or at the end of the run, but resulted in 
a loss of resolution. 
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Initially, gels were photographed on a UV transilluminator after a 5 s exposure 
using a Polaroid CU-5 Land Camera and polaroid film type 667 (camera 
settings: speed t = 1/8; aperture f:11). 
Subsequently a GDS 5000 Gel documentation system (Ultraviolet Products, 
Ltd), attached to a Sony thermal printer (Ultraviolet Products Ltd) and a 
computer was used. The optimal camera settings were an 8.5 mm lens with a 
f 1.5 aperture and a 16 mm UV filter. Once the image was captured on the 
screen it was enhanced if necessary and a text annotation added using the 
Imagestore 5000. The image was then printed and/or stored on to a computer 
disk. The stored images could then be analyzed, if required, using a gelbase 
software package (Gelbase/Gelblot
™
Windows Software, UVP Ltd). 
b Polyacrylamide gel electrophoresis (PAGE) 
Principle 
Polyacrylamide gels are formed by the polymerization of acrylamide monomers 
in a chain reaction, and the linking of these chains with N,N' -
methylenebisacrylamide (bis). The polymerization is catalysed by ammonium 
persulphate and stabilised by TEMED (N,N,N' ,N' -tetramethylenediamine) 
(Smith and Nicolas, 1983). When the bifunctional agent N,N'­
methylenebisacrylamide is included in the polymerization reaction, the chains 
become cross-linked to form a gel, the porosity of which is determined by the 
length of the chains and the degree of cross-linking. The pore size of the 
resultant three dimensional network is determined by the concentration of 
acrylamide and the ratio of acrylamide to bis. 
Polyacrylamide gels are more tedious to prepare and run than the agarose gels, 
but PAGE is particularly useful for the separation of small fragments of DNA. 
Materials and methods 30 
Procedure 
PAGE was carried out using the Hoefer Mighty Small® (Hoefer Scientific 
Instruments, San Francisco, California) vertical electrophoresis apparatus. A 
spacer thickness of 0.5-0.75 mm was found to be most suitable in terms of 
resolution. The bottom of the assembled gel mould was sealed with 2% agarose 
before pouring the gels, to prevent leakage of the acrylamide solution. 
A series of experiments using different polyacrylamide concentrations was 
carried out to find the concentration that showed an optimal resolution for each 
application. A 30% polyacrylamide stock solution was made up with 29 g of 
acrylamide and 1 g of N' -N' -methylenebisacrylamide dissolved in 100 ml of 
water and the mixture was filtered and stored at 4°C in a dark bottle. The TBE 
buffer was made up as described previously in section 2.3 iii and 10% 
ammonium persulphate was freshly prepared before use. Just prior to pouring 
the gel, 5.5 µI of TEMED was added to the solution and mixed. Using a 
pasteur pipette the solution was transferred into the gel mould. The volume of 
reagents used to cast a 18% polyacrylamide gel are given below as an example. 
Reagents Volume 
30% polyacrylamide (stock) 3 ml 
TBE 5 x 1 ml 
distilled water 1 ml 
10% ammonium persulphate 35 µI 
TEMED 5.5 µ1 
The gel polymerised in approximately 30 min at room temperature. The comb 
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was removed and the wells were washed to remove any remaining acrylamide 
solution which could produce distorted DNA bands. The gel was attached to 
the electrophoresis tank and the reservoir of the tank was filled with 1 x TBE 
buffer. 
The reaction mixture containing the sample and the appropriate loading buffer 
(0.25% xylene, 0.25% bromophenol blue, 40% sucrose in 0.5 x TBE buffer) was 
loaded into the wells using a Hamilton syringe. The gel was electrophoresed at 
the required voltage and temperature for the appropriate time. 
The gels were then stained with ethidium bromide and documented as 
described in the previous section. 
iv RESTRICTION DIGESTION 
Principle 
Genomic DNA can be cumbersome and it is often necessary to work with more 
manageable fragments of DNA These can be generated by cutting the DNA with 
bacterial enzymes known as restriction endonucleases (REs). These enzymes bind to 
and cleave double stranded DNA at specific sites within or adjacent to a particular 
sequence known as a recognition site, which may be from 4 to 7 bases long. Over five 
hundred different restriction endonucleases have been characterized and purified for 
use (Brown, 1992b ). 
Restriction enzymes are very useful in the analysis of differences occurring in the 
human genome; modifications of bases in the genome may produce new restriction 
sites or remove pre-existing ones. This variability is inherited and the restriction 
fragment length polymorphisms (RFLPs) generated by these sites, provide a large 
number of markers for tracking mutant genes that may be involved in disease. 
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Restriction enzymes have a number of other uses, for example, isolation of cloned 
DNA from vectors, cleavage of genomic DNA for hybridisation procedures, restriction 
mapping of DNA, preparation of DNA for cloning (Brown, 1992a). 
Procedure 
Samples of DNA were restricted with the appropriate enzyme for the purpose 
required. In most instances 5 µg of DNA were digested using the concentration of 
enzyme and reaction buffer recommended by the manufacturer. Care was taken in 
diluting the enzyme so that the final glycerol concentration was no greater than 5% 
(v/v), to prevent the inhibition of the enzyme activity (Sambrook et al, 1989c). The 
digestion reaction was usually carried out at 37 °C overnight. 
The reaction was terminated by the addition of EDTA (0.5 mol/1) and the restricted 
DNA fragments were then separated on agarose gel as described in Section 2.3 iii. 
v POLYMERASE CHAIN REACTION 
Principle 
The PCR was developed in 1987 by Kary Mullis in an effort to imitate the replication 
of genetic material which occurs in nature when cells divide (Wolfe, 1993). The 
technique is based on the in vitro amplification of a specific nucleic acid fragment of 
defined length and sequence. It depends upon the principle that when DNA is heated 
above a certain temperature, its two component strands separate and that when 
cooled, the strands come together and anneal. With this procedure amplification of 
> 106 fold can be obtained from very small amounts of template. In practical terms this
is achieved by means of two flanking oligonucleotide sequences called primers (20-30 
bases in length), and repeated cycles of amplification in the presence of the enzyme 
DNA polymerase and deo>-.'Ynucleotide triphosphates ( dNTPs) (Saiki, 1990). It has 
been possible to automate this procedure with the use of a thermostable enzyme 
isolated from the bacterium Thermus aquaticus, namely Taq DNA polymerase. 
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Fig 2.1. Schematic representation of PCR in which the targeted DNA seq11ence is subjected to three 
temperature dependent steps (reprod11ced with permission from Roche Diagnostic Systems). 
This technique is now used in many laboratories worldwide. It has a number of 
advantages: it is fast, sensitive with a high specificity, and has wide applications in a 
number of areas such as prenatal diagnostics, forensic medicine, detection of foreign 
organisms or many others. The PCR however also has some disadvantages. It relies 
upon knowledge of the sequence in order to design the primers, extreme care needs 
to be taken to avoid contamination, and because of limitations on the size of the DNA 
fragment that can be conveniently amplified, usually only a small part of a gene can 
be examined at any one time. 
Factors affecting the PCR 
Many complex interactions occur during the PCR and it is therefore unlikely that there 
will be one set of conditions optimal for all reactions. Minor adjustments to the PCR 
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parameters are often reqt1ired to improve the specificity and yield. Hence it is usually 
necessary to optimize the PCR for a given application, by varying certain parameters: 
a Magnesium chloride 
The concentration of MgCl2 influences the specificity and yield of an 
amplification reaction; it may affect primer annealing, strand dissociation of 
template, product specificity, enzyme activity and fidelity and may cause 
formation of primer-dimer artefacts. 
Magnesium chloride may particularly affect Taq DNA polymerase activity 
because this enzyme requires free magnesium apart from that bound by 
template DNA, primers, and dNTPs (Innis and Gelfand, 1990). The amount of 
magnesium chloride free in the PCR mixture depends on the amount of dNTPs 
present, because dNTPs apparently bind Mg2+ quantitatively. Consequently, if
the dNTP concentration is changed significantly, a compensatory change in 
MgC12 may be necessary. The MgC12 concentration in the final reaction mixture 
should be between 0.5 and 5 mmol/1 higher than the total dNTP concentration. 
In addition, high concentrations of EDTA in the PCR solution decrease the 
amount of MgCl
2 
available for the Taq polymerase. Care should be taken when 
using DNA stored in TE buffer to optimise the concentration of MgC12 in the 
reaction. In general MgC12 in the range of 1.5 to 4 mmol/1 is used (Saiki, 1990). 
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b Deoxynucleotide triphosphates (dNTPs)
The deoxynucleotide triphosphates ( dATP; dCTP; dGTP and dTTP) are usually 
added at concentrations of 200 µmol/1 for each dNTP in the reaction mix, to 
give an optimal balance between yield, specificity, and fidelity. The four dNTPs 
are used at equivalent concentrations to minimize misincorporation errors. 
c Taq DNA polymerase 
The recommended concentration range for Taq DNA polymerase is between 
1 and 2.5 units per 100 µI of reaction mixture. For amplification reactions 
involving DNA samples with high sequence complexity, such as genomic DNA, 
the optimum increases from 1 to 4 units per 100 µl of reaction mixture. 
Addition of excess enzyme may lead to amplification of non-target sequences 
(Sambrook et al, 1989d). 
d Primers 
The design of oligonucleotide primers is very important to the success of the 
PCR reaction and is usually carried out according to certain guidelines. In 
general, the primers should be between 20 and 30 nucleotides in length, 
allowing a reasonably high annealing temperature to be used (Newton and 
Graham, 1994b ); this in turns decreases the risk of non-specific binding. Primer 
pairs should avoid complementarity at the 3' end as this promotes the 
formation of primer-dimer artefacts reducing the yield of the desired product. 
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The optimal concentration of primers is 0.1 to 0.5 µmol/1; higher 
concentrations promote mispriming and non-specific bands, and may create 
primer-dimers (Innis and Gelfand, 1990). 
The melting temperatures (Tms) for a given primer pair should be similar. The 
Tm is calculated using the formula 2 (A+ T) + 4 (G + C); annealing 
temperatures are generally chosen to be approximately 5°C below the Tm. The 
percentage of GC content should be no higher than 50-60%. 
e Other components 
Other substances reported to enhance the efficiency and/or specificity of a PCR 
can be added. These include: formamide, dimethyl sulfoxide (DMSO), 
tetramethylammonium chloride (TMAC), polyethylene glycol 6000 (PEG), 
glycerol and Tween 20 (Newton and Graham, 1994b). The optimum 
concentration of these substances has to be determined empirically. 
The major drawback of these components is that no single one can be said to 
have a beneficial effect in all PCRs. 
f Cycling conditions 
As mentioned previously the PCR is performed by incubating the reaction 
mixture at three different temperatures corresponding to the three steps of 
denaturation, annealing and extension. 
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Double-stranded DNA is denatured at 94°C. Incomplete denaturation allows
the DNA strands, to snap back reducing product yield or can even result in 
PCR failure. Thus it is sometimes helpful to carry out an initial denaturation 
step at 93-95°C for a few minutes, prior to the start of the PCR.
The primers are allowed to anneal to their complementary sequences by briefly 
cooling to 40-60°C. This is followed by heating to 70-75°C to extend the
annealed primers with the Taq polymerase. The primer extension time depends 
upon the length and concentration of the target sequence and upon 
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Fig 2.2. PCR temperature cycling profile. Step I: Denaturation of DNA template at around 93°C-
950C. Step 2: Oligom1cleotide primers anneal to the denalllred template at temperahtre 40-6(J'C. 
Step 3: Primer is extended at 72°C. Steps 1 to 3 constitllle one cycle of the PCR. This process is then 
repeated for the appropriate 1111mber of cycles for a given PCR. 
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The optimum number of cycles depends mainly upon the starting concentration 
of target DNA when all other parameters are optimized. Too many cycles may 
increase the amount and complexity of non-specific background products and 
may also result in product inhibition. 
The amplification reaction is not infinite. After a certain number of cycles the 
desired amplification fragment gradually stops accumulating exponentially; this 
is called the plateau effect. The point at which a PCR reaction reaches its 
plateau depends primarily on the number of copies of target originally present 
in the sample and on the total amount of DNA synthesized. Some of the 
possible causes of the plateau effect are substrate excess, competition by non­
specific products and product reassociation. 
Denaturation of DNA template 
The first few rounds of a PCR are very important since they determine the final yield. 
Thus it is vital that the DNA is completely denatured particularly when using high 
molecular weight DNA as a template. Boiling of the DNA for up to 10 min and 
immediate chilling on ice prior to being added to the PCR mixture has been shown 
to greatly enhance the amplification process. Boiling the DNA before PCR also 
reduces the amount of primer oligonucleotide required (Abbott et al, 1988). 
All PCRs in this study were carried out using a Hybaid®DNA Thermal Cycler 
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(Hybaid Ltd. UK). Exact details of primer sequences, reagent concentrations and 
cycling conditions are described in the relevant sections. 
vi SOUTHERN HYBRIDISATION 
Principle 
Fragments of DNA which have been separated by electrophoresis are rendered single 
stranded and transferred from the gel on to a nylon or nitrocellulose membrane. After 
fixing the DNA on the membrane by crosslinking under UV radiation it is hybridised 
with a suitably labelled probe in order to detect a specific sequence (or gene) in the 
DNA. The transfer method was originally developed by Ed Southern (Mathew, 1983) 
for DNA molecules (Southern blot) but has been adapted for RNA (northern blot) 
and proteins (western blot). 
Procedure 
The procedure used for Southern hybridisation has several steps such as transfer of the 
DNA to a membrane, preparation and labelling of the DNA probes, and finally the 
hybridisation and visualization. These are described separately in the following 
sections. 
Both oligoprobes (short 20-30 base sequences) and large DNA probes can be used for 
Southern hybridisation. The choice is dependent on the application. Oligoprobes are 
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usually synthesized on a DNA synthesizer while DNA probes are obtained from the 
culture of E.coli which harbour plasmids in which the DNA of interest has been 
cloned. Details of the probes used are provided in the relevant sections. 
a Preparation of DNA probes 
Culture of E.coli 
Bacteria (2 to 3 colonies picked off an agar plate) containing the 
plasmid/probe of interest were grown in 3 ml of Luria-Berti (LB) broth (lOg/l 
Tryptone, 5 g/1 yeast extract, 10 g/1 NaCl) containing the appropriate antibiotic 
in a 5 ml Bijou bottle by incubating overnight at 37°C with vigorous shaking. 
Greater amplification of the plasmid was obtained by treating the cells in late 
log phase with an inhibitor of protein synthesis, such as chloramphenicol (10-20 
µg/ml). This inhibits bacterial chromosomal DNA replication but allows 
continued replication of the plasmid DNA (Sambrook et al, 1989a). 
Isolation of plrumid DNA 
The culture was spun at 1200 g for 5 min to harvest the bacteria. The medium 
was drained off to leave the bacterial pellet as dry as possible. 
A Wizard™DNA purification system (Promega Corporation, USA) for the 
Materials and methods 41 
isolation of plasmid DNA was used according to the manufacturer's 
instructions. Briefly, the bacteria cells were lysed in an alkali solution and the 
free plasmid DNA bound to a silica-based resin at a high salt concentration. 
The resin was then washed to remove salts or contaminants and the DNA 
eluted from the resin at low salt concentration by centrifugation, and stored at 
4°C or -20°C. 
&traction of the DNA probe from the plasmid 
The DNA insert was removed from the plasmid by restriction with the 
appropriate RE as described in Section 2.3 iv. A one hour incubation at 37°C 
was found to be sufficient to cut the plasmid DNA. The restricted DNA was 
then electrophoresed on a 1 % agarose gel with the appropriate molecular 
weight marker. 
The band corresponding to the DNA insert was identified, and extracted from 
the gel using a Qiaex Kit (Qiagen Ltd, Promega Corporation, Madison, USA). 
The principle of this kit is based on solubilisation of agarose and selective 
adsorption of nucleic acids to silicagel particles in the presence of high 
concentrations of salt. This was followed by the elution of the nucleic acids at 
low salt concentrations using centrifugal force. 
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b Labelling of probes 
The choice of label and labelling technique depends on the size of the probe 
to be labelled. In this study the DNA probe was labelled with a-32P-dCTP using 
the Megaprime
TM 
DNA Labelling Systems Kit (A.mersham, International plc, 
England) employing the random priming reaction. For oligoprobes a non­
radioactive DIG Oligonucleotide 3' -End Labeling Kit was used (Boehringer 
Mannheim GmbH, Germany). 
b.l Random priming method 
l>Hhci ··1e "'··· .-. .P.,.,.,
This method is based on the use of a random sequence of nonanucleotides, 
used as primers, to start DNA synthesis on a denatured template DNA. This 
occurs at numerous sites along its length. The K.lenow polymerase in the 
reaction mix adds randomly a 32P radiolabeled nucleotide (in this case 32P­
dCTP) and unlabelled dNTPs to the single stranded DNA template and thus 
the newly synthesized DNA is radioactively labelled. 
The K.lenow fragment of DNA polymerase is used specifically because it lacks 
the 5'-3' exonuclease activity associated with DNA polymerase 1 and thus 
ensures that labelled nucleotides incorporated by the polymerase are not 
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subsequently removed. The presence of exonuclease activity can be troublesome 
because it degrades the 5'terminus of primers that are bound to DNA 
templates (Sambrook et al, 1989c). 
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Fig 2.3. Schematic diagram showing the random primer reactio11 which allows incorporation of 
radiolabelled bases using Kienow polymerase. 
The labelling procedure was carried out according to the manufacturer's 
instructions. 
The percentage of incorporation of 32P-dCTP varied between 30-60% and the 
specific activity was between 1.3-2.5 x 109dprn/ µg.





The principle 1s based on the addition of digoxygenin dideoxyuridine 
triphosphate (DIG-ddUTP) to the 3' end of the oligonucleotide DNA template 
(probe) with the aid of the terminal transferase enzyme. 
The procedure was carried out according to the manufacturer's instructions. 
c DNA transfer 
There are several methods for the transfer of DNA on to a solid support such 
as nylon or nitrocellulose, namely capillary, electrophoretic or vacuum transfer. 
In this study transfer by vacuum was chosen because of its efficiency and the 
short period of time required for complete transfer. 
The vacuum transfer was carried out as follows: 
The gel was placed in contact with a nylon membrane (Hybond, Amersham) 
supported on a porous screen over a vacuum chamber, taking care to ensure 
that the vacuum was applied evenly over the entire surface. 
A depurination solution (0.2 mol/1 HCl) was washed through the gel for 20 min 
under vacuum. This allowed the DNA to be broken into smaller pieces to 
facilitate the transfer process. 
A denaturation solution (1.5 mol/1 NaCl and 0.5 mol/1 NaOH) was washed 
through the gel for 30 min to denature the double stranded DNA. 
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Finally the DNA was transferred to the membrane by washing the gel under 




and 10 mol/1 NaOH for 30 min. 
d Hybridisation 
frln�teJ! 
When single-stranded DNA is placed in contact with a complementary single-
stranded DNA sequence, the two DNA molecules bind to each other by 
hydrogen bonding between the bases. This binding, or hybridisation, forms the 
basis of the techniques used for the detection and semi-quantitation of specific 
nucleic acid sequences. 
DNA probe 
The initial step was a prehybridisation (without labelled probe) to block the 
non-specific binding sites on the membrane. This was carried out by rotating 
the membrane for 2 h at an appropriate temperature in 30 ml of hybridisation 
solution containing 0.5 mol/1 NaHPO
4 
(pH 7.2), 0.001 mol/1 EDTA, 7% SDS 
and 1% BSA. 
This was followed by overnight hybridisation in 20 ml of the same solution 
containing labelled probe. Usually 12.5 ng/blot (25 µCi) was used. The probe 
was previously denatured by boiling for 5 min and chilling on ice to ensure the 
separation of the double-stranded DNA. 
After hybridisation, the membrane was washed twice for 15 min under 
conditions of higher stringency in a solution of 0.04 mol/1 NaHPO
4 
(pH 7.2) 
containing 1 % SDS (Meling et al, 1993). 
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Oligoprobes 
Conditions used for hybridisation of short sequences of DNA were based on an 
adaptation of the 3' -End Labelling and Hybridisation Kit (Boehringer) 
instructions. The nylon membranes were carefully cut to include only the region 
where the bands were expected in order to reduce the amount of hybridisation 
solution required. No prehybridisation step was necessary and the duration of 
the hybridisation (approximately 1 h) was much shorter than for the DNA 
probes. 
e Visualisation 
e.1 DNA probes 
The hybridisation of the 32P labelled DNA probe to the DNA of interest was 
visualized by means of autoradiography, in which the radioactive isotope reacts 
with an X-ray film resulting in a visible signal. 
Pf6�edfr e 
The wet nylon membrane ( containing the hybridised DNA) was wrapped in 
Glad Wrap plastic, and placed in an X-ray cassette. In a darkroom the 
membrane was covered with a sheet of X-ray film (Hyperfilm
™
MP, Amersham) 
and an intensifying screen to increase the signal. The cassette was then placed 
at -70°C to stabilize the ions that form the latent image of the radioactive 
source. The length of exposure depended on the intensity of the signal and was 
usually from 1 to 2 weeks. 
The X-ray film was developed manually as follows: the film was placed in a 
developer solution diluted 1:3 for 1 min, washed in water for 1 min and finally 
in a fixer solution for 1 min (FX-Universal Agfa chemicals). 
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After development of the X-ray film, the position of the visible signal or band 
was examined relative to an image of the original gel to determine the size of 
DNA fragment to which the probe was hybridised. 
e.2 Oligoprobes 
The visualization of the DIG-labelled oligoprobes was carried out as instructed 
by the manufacturer. Briefly the hybridized molecules were visualized by the 
production of an enzymatically derived insoluble blue precipitate following the 
reaction in which the oligonucleotide labelled at the 3' end with DIG-ddUTP 
reacts with an antibody conjugate. 
vii SINGLE STRAND CONFORMATIONAL POLYMORPHISM (SSCP) 
Principle 
Single strand conformational polymorphism analysis depends on the principle that the 
electrophoretic mobiliLy of a molecule within a gel matrix is sensitive to the size, 
charge and shape of the molecule. Under non-denaturing gel conditions single 
stranded DNA has a folded structure that is imposed by intramolecular interactions 
dictated by its sequence. In SSCP analysis a single nucleotide difference between 
similar sequences is sufficient to alter the folded structure of one sequence relative to 
the other. This conformational change is detected as a mobility difference upon gel 
electrophoresis. The sensitivity of the method allows detection of most single 
nucleotide differences in a fragment composed of several hundred nucleotides (Newton 
and Graham, 1994). 
Practical considerations 
Several factors contribute to the success of SSCP analysis. These are dealt with 
individually in this section. 
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a Polymerase chain reaction 
The first step in the preparation of DNA for SSCP analysis is the amplification 
of the region(s) of interest. Since optimal sensitivity for SSCP is obtained with 
DNA sequences between 300 to 400 bases in length ( Hongyo et al, 1993; 
Newton and Graham, 1994a), it is sometimes necessary to examine the region 
of interest one section at a time. In the case of the p53 gene the exons 5 to 8 
in which more than 90% of mutations are found, all comprise less than 183 bp 
and therefore each exon can be amplified intact. In order to ensure that the 
entire exon is covered, primers were chosen complementary to regions in the 
intrans flanking each exon. 
The primer sequences and details of the PCRs are described m detail m 
Chapter 5. 
b Analysis of single stranded DNA 
Several approaches to the analysis of single stranded DNA are available. The 
original SSCP protocol uses radiolabelled nucleotides to generate a 
radiolabelled PCR product, which is then diluted, denatured by heat, and 
electrophoresed at high voltage on a large formatted ( 40 x 20 cm) non­
denaturing polyacrylamide gel (Orita et al, 1989). The method depends heavily 
on experimental conditions that optimize migration differences of the single 
stranded DNA conformation. Thus, factors such as the addition of glycerol to 
the polyacrylamide, modification of the temperature and electrophoretic 
conditions may result in greater levels of sensitivity. Others supports such as 
Hydrolink MDE and Hydrolink D-5000 have also been used in an attempt to 
improve the sensitivity of SSCP (Soto and Sukumar, 1992). 
Recently the use of non-radioactively labelled primers has been introduced. 
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Following PAGE, the single stranded fragments can be visualised with 
chemiluminescence, silver nitrate or ethidium bromide (Orita et al, 1989; 
Hongyo et al, 1993; Dockhorn-Dworniczak et al, 1994). 
The approach adopted in this study is that of Hongyo et al, (1993) in which non 
radio-labelled primers are used. Single stranded fragments are detected using 
ethidium bromide, on a small polyacrylamide gel run at high voltage. 
c Factors affecting SSCP analysis 
The factors discussed here are specific for the SSCP analysis used in this study. 
However, the principles are applicable to SSCP carried out using a range of 
different electrophoresis and detection systems. 
r eht.peraJUfe. 
The control of the temperature within the gel unit is important for consistent 
detection of single strand bands (Hongyo et al, 1993). Thus recirculation of 
water through a thermostatically controlled system is recommended to maintain 
the running buffer at constant temperature. The ideal temperature is dependent 
on the conformation of the DNA fragment and is determined empirically for 
each product. 
re;.� pN>�ud co�ceiffraifon 
The concentration of PCR product loaded on to the gel affects the resolution 
of the bands. It would appear that at least a 1:3 dilution is required to avoid 
significant amounts of double stranded DNA and blurred single stranded bands 
in the PAGE gel. This phenomen is probably due to the partial reannealing 
that occurs at high DNA concentrations (Hongyo et al, 1993). 
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The use of a denaturant to keep the two DNA strands separated is important 
to the success of the method. One denaturant used is methylmercury hydroxide, 
which prevents excessive reannealing of the DNA strands prior to entry into the 
gel. The use of less hazardous compounds such as sodium hydroxide is also 
recommended (Hongyo et al, 1993). 
The composition of the loading buffer would appear to affect resolution. 
Buffers containing 15% Ficoll with or without formamide generally result in the 
sharpest bands (Hongyo et al, 1993). 
ItG:l'f�r �YP.'.� a1'� concenfr�do
ii 
The type and concentration of the running buffer in the gel chamber can also 
affect the clarity of the SSCP bands. In most cases 1-1.5 x TBE yields the 
sharpest SSCP bands when using polyacrylamide gels (Hongyo et al, 1993). 
V�!!?.g� 
A constant voltage between 300 or 400 V produces the best sensitivity and 
sharpness of the bands in SSCP analysis (Hongyo et al, 1993). Under these 
conditions however temperature control is essential. Gels can also be 
satisfactorily run at lower voltages for longer periods, usually overnight at a low 
temperature. 
Details of the gel concentrations, electrophoresis conditions and other factors used in 
this study for SSCP analysis of exons 5, 6, 7 and 8 of the p53 gene are documented in 
Chapter 5. 
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3.1 INTRODUCTION 
Reports in the literature indicate that 80-90% of mutations in the p53 gene are 
associated with loss of the corresponding allele, also known as loss of heterozygosity 
(LOH) or reduction to homozygosity (Sidransky et al, 1991). This relationship between 
LOH and mutations can therefore be used to screen tumours for mutations (Delattre 
et al, 1989; Sidransky et al, 1991) and has been shown to be useful in several tumour 
types. For example, in human hepatocellular carcinoma an association with LOH was 
found in 80% tumours manifesting p53 mutations (Fujimoto et al, 1994 ), in breast 
tumours this relationship was found to be 83% (Tsuda and Hirohashi, 1994), and in 
oesophageal squamous cell carcinoma 89% (Maesawa et al, 1994 ). 
In tumours of the cervix very little information is available on LOH in the p53 gene. 
Three studies have been reported on a small number of patients which indicate that 
both LOH and p53 mutations in this tumour type occur with a much lower frequency 
(Crook et al, 1992; Fujita et al, 1992; Busby-Earle et al, 1993). The purpose of this 
study therefore, was to undertake a survey of tumours of the cervix from black South 
African women for LOH of the p53 gene as an indication of the prevalence of p53 
aberrations in a local population. 
The most commonly used technique for the identification of LOH is Southern analysis 
in which appropriately restricted DNA is hybridized with a 32P-labelled DNA probe 
specific to the gene of interest or an adjoining region (Eccles et al, 1992). In this way 
restriction fragment length polymorphism (RFLPs) or large variable number of tandem 
repeats (VNTRs) can be detected. This method, however, is cumbersome, expensive, 
often uninformative and requires the use of radio-isotopes. Consequently other 
approaches have been sought, for example, the amplification of genetic regions in 
which dinucleotide, triplet or other VNTRs are common. 
LOH as a screen for p53 mutations 54 
This chapter describes one such technique in which a VNTR region in intron 1 of the 
p53 gene is amplified by PCR and LOH determined in heterozygotic individuals. For 
the purpose of comparison, a subset of tumours was also analysed by conventional 
Southern hybridisation. The results obtained using these two approaches are presented. 
3.2 LOSS OF HETEROZYGOSITY BY AMPLIFICATION OF A VNTR 
POLYMORPHISM 
i INTRODUCTION 
The method used is based on a published technique in which a VNTR region in intron 
1 of the p53 gene was amplified by PCR and subjected to polyacrylamide gel 
electrophoresis (PAGE) (Hahn et al, 1993). Normal and tumour DNA from individuals 
showing allele heterozygosity was examined for the loss of one allele. 
ii PRINCIPLE 
Different numbers of repeats in a VNTR region of the genome result in different 
length fragments which can be detected on PAGE following PCR (Fig 3.1 a). When 
two alleles are homozygous with respect to the number of repeats (AA), only one band 
is detected on PAGE. Heterozygous alleles with differing numbers of repeats (AB, 
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AC) result in two bands. By making comparisons between DNA from tumour tissue 
and normal cells, such as lymphocytes, loss of one allele can be clearly demonstrated 




















AA AB AC 
--.. . 
B T B T B T 
B = blood 
T = tumour 
Fig 3.1. Schematic represe11tatio11 of (a) a VNTR region of a gene with 'A', 'B', 'C' representing examples of 
different alleles and (b) loss of allele in the tumour DNA from a heterozygous individual. 
iii METHODS 
Clinical material 
Cervical tumours and blood from 123 patients were collected, stored and the DNA 
isolated as described in Section 2.3. Special care was taken to avoid contamination of 
the tumour with surrounding normal tissue or blood. 
All patients were black women aged between 20 and 91 years with primary squamous 
carcinoma of the cervix. Tumours were histologically confirmed before acceptance into 
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the study. A total of 22 patients was subsequently excluded because insufficient tumour 
tissue was available, or tumour or blood DNA did not amplify satisfactorily. Thus 
results are reported on 101 patients. 
Polymerase chai,n reaction 
The general principles and factors influencing the PCR are outlined in Chapter 2. In 
the present chapter the protocol used to amplify a VNTR region in intron 1 of the p53 
gene is described in detail. 






These primers flank the following region of tandem repeats in intron 1 of the p53 
gene: (Arrows and numbers show the orientation and position of the PCR primers 
which are indicated by capital letters) 
8946 .... 
5' ACTCCAGCCTG GGCAA T AA GAG Ctgagactccgtctcaaaataaaataaaa .......... taaaataaaa 
-9076
taaaataaaaaaagaaaagagcctgccattaaaggaGCTG1TIGGTAGGGGATGTITIGT 3' 
Primer 1 is a sense strand sequence which binds to the complementary antisense DNA 
strand running from 3' to 5'. Primer 2 is an antisense sequence and binds to the 
complementary sense DNA strand running from 5' to 3
1
• The expected PCR product 
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is in the region of 131 bp, depending on the number of repeat sequences present. The 
melting temperatures (Tms) are 72°C and 70°C for the first and second primers, 
respectively, and were calculated as described in Section 2.3 v. 
The primers were synthesized on a Milligen Oligonucleotide Synthesizer in the 
Department of Biochemistry at the University of Cape Town. 
Optimization of the PCR 
a DNA integrity 
The integrity of the DNA was checked by running 1 µg of DNA from blood 
and tumour samples on a 1 % agarose gel with Marker II (Boehringer) as 
described in Section 2.3 iii. The DNA was of high molecular weight and showed 
no degradation as can be seen in Fig 3.2. 





Fig 3.2. Agarose gel (1%) showing 1 MJ blood DNA from seven individuals. 
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b Concentration of MgCl
2 
A magnesium chloride concentration of 1.5 mrnol/1 is generally adequate for 
the PCR. However, the DNA used in this study was stored in a buffer 
containing EDTA and it was therefore necessary to optimise the concentration 
of MgC1
2
• This was done by carrying out a series of reactions with 
concentrations of MgC1
2 
ranging from 2 to 4 mrnol/1. Results indicated that 2 
mmol/1 MgC1
2 
was optimal for the concentration of reagents used. Higher 
concentrations resulted in an increase of non specific bands (Fig 3.3). Some 
amplification reactions were also carried out with 1.5 mmol/1 of MgC1
2 
(results 





1 2 3 4 5 
Fig 3.3. Agarose gel (2%) showing the PCR products obtained with different co11ce11tratio11s of 
MgCli- Lane 1, molecular weight ma,ker V (Boehringer); lane 3, 2 mmol/l MgCl:z,· lane 4, 3 mmol 
MgCl:z,· lane 5, 4 mmol/1 MgCli-
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c Concentration of primers and Taq DNA polymerase 
The optimum concentration of primers was determined by carrying out 
different experiments using 100 nmol/1, 200 nmol/1, 400 nmol/1 of each primer 
and 1 or 2 units of Taq DNA polymerase. Results indicated that the optimal 
concentration of primers was 200 nmol/1 using 1 unit of Taq (lane 6, Fig 3.4). 
1 2 3 4 
Hint I
(bp) 
5 6 7 8 
140 
118 
Fig 3.4. Agarose gel (2%) showing the PCR products obtained with differe11t concentrations of 
primers and amounts of Taq polymerase. The co11centratio11s of primers were lane .Z 400 11mol/l; 
lane 3, 200 nmol/1; lane 4, 100 mnol/1 with 2 units of Taq polymerase; lane 5, 400 11mol/l; lane
� 200 1111101/1; lane 7, 100 nmol/l with 1 unit of Taq polymerase; lane 8, molecular weight marker
Hinfl (Promega); lane I, 110 DNA. 
LOH as a screen for p53 mutations 60 
d Concentration of DNA 
To determine the optimum concentration of DNA different reactions were 
carried out using between 10 and 29 ng of boiled DNA in a total PCR mixture 
of 25 µl. The concentration of MgC1
2 was 2 mmol/1 with 200 nmol/1 of primers 
and 1 unit of Taq. The total volume for the PCR mixture was 25 µl except for 
one reaction (lane 7, Fig 3.5) in which the amount of all reagents used was 
doubled and the amount of boiled DNA was 14 ng. The optimal amount of 
DNA for successful amplification was found to be approximately 14 ng of 
boiled DNA with 200 nmol/1 of primers, 2 mmol/1 MgCl
2 
and 1 unit of Taq in 
a total PCR mixture of 50 µl (lane 7, Fig 3.5). Boiling of the DNA prior to use 





1 2 3 4 5 6 7 8 
Fig 3.5. Agarose gel (2%) showing the PCR products obtained with differe11t co11ce11tratio11s of DNA. 
Lane 1, molecular weight marker Hi11fl (Promega); lane .Z 110 DNA co11trol, the co11ce11tratio11s of 
DNA were as fallows, lane 3, 29 11g/25 µ reaction mixture; lane 4, 19 ng/25 µ; lane 5, 
14 ng/25 µ; lane 4 10 ng/25 µ; lane 7, 14 11g/50 µ; lane 8, 14 ng/25 µ. All the DNA samples 
were boiled prior to being added to the PCR mix except the 011e in lane 8. The total volume in the 
PCR mixture was of 25 µ except for lane 7 which was 50 µ. 
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PCR procedure 
Having optimized the PCR as described above, tumour and blood DNA from the 
patients was amplified as follows: each PCR reaction contained 14 ng of DNA, 5 µl 
of Taq polymerase buffer, 2 mmol/1 of MgC1
2
, 200 nmol/1 of each primer, 200 µmol/1 
of each dNTP and 2 units of Taq DNA polymerase (Promega) made up to 50 µl with 
sterile deionized water. 
A master mix of the reagents common to the PCR was made up in a 1.5 ml eppendorf 
before each run. The mixture ( excluding the DNA) was then aliquoted to each 
reaction tube using a positive displacement pipette. This procedure reduces tube to 
tube variation and minimises the risk of contamination. 
The DNA to be amplified was boiled for 10 min and quickly chilled on ice prior to 
being added to each PCR mixture. After spinning briefly a few drops of mineral oil 
were added to each tube to seal the reaction mix and prevent condensation. Silica gel 
was used in the heating block holes to ensure good thermal contact. Each run included 
a reaction mix without DNA to monitor for contamination of Lhe reagents. 
The PCR was carried out in a Hybaid®DNA Thermal Cycle (Hybaid Ltd. UK). After 
an initial denaturation step at 93°C for 5 min each reaction mix was subjected to 35 
cycles at the following temperatures: 
93°C for 1 min (denaturation) 
64°C for 1 min (annealing) 
72°C for 1 min (extension) 
A final 10 min extension at 72°C completed the reaction. The annealing temperature 
chosen was approximately 5°C below the lowest primer Tm. 
Analysis of the PCR amplified product by polyacrylamide gel electrophoresis (PAGE) 
A 25 µ1 volume of the PCR product mixed with 2 µl of loading buffer was loaded on 
to an 18% polyacrylamide gel (as described in Section 2.3 iii). The gel was 
LOH as a screen for p53 mutations 62 
electrophoresed at 4°C for 16 h at 60 V. Two molecular weight markers (Marker V­
Boehringer and Hinfl-Promega) were included on each gel. 
Precautions taken during the PCR procedure 
There are many potential sources of contamination in the PCR. In this study several 







Reactions were set up in a designated area in a laminar flow cabinet. 
Equipment and reagents used for the PCR were kept separately from general 
laboratory equipment. 
DNA was added to the reaction mixture in a separate room. 
Gloves were changed frequently. 
Reagents such as buffers and dNTPs were prepared in batches and aliquoted 
for storage in convenient lots to prevent contamination of stock solutions. 
Positive displacement pipettes and pipette tips containing barriers to prevent 
aerosols were used. 
Each run included a control with no DNA and regular inclusion of a positive 
control or a well characterized sample. 
iv RESULTS 
Allele frequency 
Five different alleles were detected, each differing by the number of tandem repeats. 
These were designated A, B, C, D and E. The allelic frequency was: A = 0.20, 
B = 0.56, C = 0.12, D = 0.07 and E = 0.05. 
Using the molecular weight markers, the sizes of the 5 bands seen on the 
polyacrylamide gel were estimated to range from 118 to 144 bp. 
A number of different genotypes were detected, examples of which are shown in 
Fig 3.6. The most common genotypes were BB and AB which accounted for 38% and 
11 %, respectively, of the samples studied. 
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Fifty three (52%) of individuals were found to be heterozygous for the VNTR 
polymorphism while the remaining 48 ( 48%) were homozygous. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Fig 3.6. Polyac,ylamide gel ( 18%) showing different genotypes for the VNTR in i11tro11 1 of the p53 gene. 
Lanes 4 and 12 are Ma,ker V and lanes 5 and 13 are Ma,ker Hinfl. 
Non specific bands were occasionally detected in some individuals. However these 
were always larger than the VNTR bands and therefore did not constitute a problem. 
Loss of allele 
Of the 53 pairs of tumour and blood DNA which were heterozygous and potentially 
informative, two ( 4%) showed clear loss of one allele as indicated on the 
polyacrylamide gel by the absence of one band in the tumour samples (Fig 3.7). 
Sample 107 showed a very faint band in the position of the second allele. This most 
likely reflects contamination with normal tissue or blood. 
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Southern hybridisation is the most commonly used technique for the determination of 
LOH. Restricted fragments of DNA are transferred to a nylon membrane and 
hybridised with a 32P-DNA probe. Comparison of bands seen in normal and tumour 
DNA allows detection of the loss of heterozygosity in tumour tissue. 
ii PRINCIPLE 
The principle of Southern hybridisation is described in full in Section 2.3 vi. 
Loss of heterozygosity is generally defined as a greater than 40% decrease in signal 
intensity of at least one allele in the tumour sample when compared with the 
respective blood (Dalbagni et al, 1993). 
iii METHODS 
Clinical material 
Thirty seven (37%) of the 101 tumours in which allele loss was determined by PCR 
detected VNTR polymorphism, were chosen randomly for Southern hybridization 
analysis. 
DNA probe 
The genomic DNA probe used to detect LOH of the p53 gene is designated pYNZ22. 
It is a 1.6 kb fragment which recognises a VNTR sequence within the 17p13 locus 
telomeric to the p53 gene (Fig 3.8). The probe purchased from the American Type 
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Culture Collection (Rockville, Md) was available as a BamHI insert in the plasmid 





Fig 3.8. Schematic diagram of chromosome 17 showing the localization nf the pYNZ22 probe. 
a Preparation of the DNA probe 
The culture of E.coli and isolation of the plasmid DNA was described in 
Chapter 2. Briefly, the E.coli were grown for 24 h in LB medium and treated 
with chloramphenicol to obtain a high copy number of plasmids containing the 
DNA probe. The bacterial cells were then ruptured at an alkali pH to liberate 
the plasmids from which DNA was extracted. Finally, the DNA insert was 
separated from plasmid DNA by restriction with the BamHI enzyme as follows: 
approximately 6 µg of plasmid DNA were incubated with 9 units of restriction 
enzyme/ µg DNA at 37°C for 1 h. The reaction was stopped by adding 0.5 mol/1 
EDTA (pH 8). 
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The DNA mix was separated by electrophoresis on a 1 % agarose gel (Fig 3.9). 
The 1.6 kb fragment representing the p YNZ22 DNA probe was extracted from 







Fig 3.9. Agarose gel (1%) showing BamHI restricted pBR322 plasmid DNA. The 1.6 kb fragment 
co,responds to the pYNZ22 inse,t and the 4.4 kb fragment to the pBR322 vector. 
b Labelling of the DNA probe 
The p YNZ22 probe was labelled with a32P-dCTP using a Megaprime-Random 
Priming Kit (Amersham) following the instructions of the manufacturer. 
Incorporation of radioactivity ranged from 30 to 40% and the specific activity 
was of the order of 2.5 x 109dpm/ µg.
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Southern blot 
Genomic DNA (5µg) from blood and tumour was digested with 20 units of BamHI by 
incubating at 37°C overnight (Section 2.3 vi). The reaction was stopped with 0.5 mol/1 
EDTA (pH 8). The restricted DNA was transferred on to a nylon membrane by 
vacuum transfer as described in Section 2.3 vi. 
Hybridisation 
A 2 hour prehybridisation at 64°C in 30 ml of hybridisation buffer (0.5 mol/1 NaHPO
4 
pH 7.2, 0.001 mol/1 EDTA, 7% SDS and 1 % BSA) was followed by hybridisation 
(overnight) at the same temperature, in 10 ml of the same buffer which also contained 
25 µCi of 32P-DNA probe per blot. The hybridisation procedure was carried out in a 
Hybaid Mini Hybridization Oven (Hybaid Ltd, UK). 
After hybridisation the membranes were washed for 15 min (2x) at 64°C in 0.04 mol/1 
NaHPO
4 
(pH 7.2) containing 1 % SDS. 
The membranes were kept moist by wrapping in Glad Wrap plastic and exposed to an 
X-ray film for 7-14 days at -70°C using an intensifying screen before being developed 
as described in Section 2.3 vi. 
Optimization of DNA concentration 
The minimum amount of restricted DNA that could be efficiently hybridised and 
visualised was determined in a series of experiments in which amounts of DNA 
ranging from 4 µg to 10 µg were analysed. It was found that the minimum amount of 
restricted DNA that yielded satisfactory results was 5 µg (Fig 3.10). 
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45 6 7 8 9 10 
Fig 3.10. AutoradioJ.:raph showing hybridisation of DNA, ranging from 4 HJ to 10 HJ, to 32P-pYNZ22 DNA 
probe. 
iv RESULTS 
Of the 37 paired samples of blood and tumour that were analyzed, 23 were 
heterozygous as indicated by two bands in the autoradiograph. The fragment sizes 
ranged from 0.5 to 1.3 kb. The remaining 6 tumours and bloods showed single alleles. 
There were 8 samples which were impossible to assess due to insufficient DNA 
transfer and/ or inadequate hybridisation. In none of the 23 heterozygous tumours was 
there any evidence of loss of allele and neither was there any indication of loss of 
signal intensity in any of the 6 homozygous tumours (Fig 3.11). 









40 40 41 41 
B T B T 
Fig 3.1 J. Autoradiograph showi11g VNTRs detected by 32P-pYNZ22 DNA probe in paired samples of blood 
and tumour. Samples 408-407> 418-41T and 428-42T were heterozygous a11d samples 578-57T and 858-BST were 
homozygous. 
3.4 DISCUSSION 
LOSS OF ALLELE 
The results of this study suggest that the incidence of LOH of the p53 gene in cervical 
carcinomas from Black South African women is low. Only two ( 4%) out of 53 
informative tumours demonstrated LOH as detected in a polymorphic region of 
intron 1 of the p53 gene while none of a subset of 29 tumours showed evidence of 
LOH using Southern hybridisation to a VNTR region telomeric to the p53 gene. 
These findings contrast strongly with the frequency of LOH reported in other tumour 
types. For example, allelic deletions on chromosome 17p have been reported in 48% 
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cases of ovarian tumours (Frank et al, 1994), 58% of hepatocellular carcinomas 
(Fujimoto et al, 1994) and 76% of osteosarcomas (Toguchida et al, 1989). However the 
low frequency of LOH in carcinoma of the cervix reported here is in excellent 
agreement with the incidence reported in the three studies that have been published 
on this particular tumour type. Some authors (Fujita et al, 1992; Crook et al, 1992) did 
not find any evidence of LOH of the p53 gene in studies on 10 and 17 squamous 
cervical tumours, respectively, while another study (Busby-Earle et al, 1993) reported 
LOH in 3 out of 20 informative cases evaluated. Recently a Japanese study has 
reported a 35% frequency of allelic loss on chromosome 17p in a variety of uterine 
tumours; however these results were obtained using a selection of genomic probes 
(Jones et al, 1994 ). 
The low incidence of LOH in carcinoma of the cervix, implies that if tumour 
suppressor genes are involved in the aetiology of this tumour, they may be found on 
chromosomes other than chromosome 17, as has been suggested in the literature (Riou 
et al, 1988; Yokota et al, 1989; Jones et al, 1994). On the other hand, the low 
frequency of LOH in carcinoma of the cervix, and by implication the low rate of p53 
mutations suggests that tumours of the cervix may arise through an alternate 
mechanism. One possibility is a viral involvement. It is known that HPV which 
commonly infects cervical epithelium produces an oncoprotein that complexes to the 
normal p53 protein. This inactivation of the normal protein results in unregulated cell 
growth. To determine the possibility of a relationship between the p53 mutation status 
and HPV infection, all tumours examined for LOH of the p53 gene in this study were 
also examined for the presence of HPV DNA. The results are presented in the next 
chapter. 
With respect to the two tumours in this study which showed LOH, reports in the 
literature (Baker et al, 1989; Crook et al, 1992; von Deimling et al, 1992; Nishida 
et al, 1993) suggest that they have a high probability of containing a p53 mutation. 
These tumours were therefore examined for the presence of mutations by single strand 
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conformational polymorphism (SSCP). This technique which allows rapid detection of 
point mutations is described together with the results in Chapter 5. 
ii Methodology 
In this study a novel approach has been used to detect LOH in which a short VNTR 
polymorphic region was amplified and examined by PAGE. The results, reflecting a 
low incidence of LOH, would appear to compare well with other studies on carcinoma 
of the cervix using Southern hybridisation. In addition there was a 100% agreement 
in the results obtained in the subset of tumours in this study which were examined by 
both methods. Due to the small tumour size and limited DNA available, a direct 
comparison of the tumours exhibiting LOH by the PCR based VNTR method with the 
Southern hybridisation technique was not possible. 
From the point of view of convenience, the PCR based method has distinct advantages 
over the conventional DNA hybridisation technique. These include improved 
resolution, reliability, time taken to obtain results (24 h as opposed to at least 10 
days), cost factors and a move away from the use of radioactivity. However the PCR 
based method also has disadvantages, in particular the fact that only approximately 
50% of individuals are heterozygous and thus potentially informative for this particular 
polymorphism. One approach to increasing the number of informative cases would be 
to examine other polymorphic regions along the p53 gene and to establish additional 
PCRs and possibly even a multiplex PCR so that amplification of several loci could 
be carried out simultaneously. This approach should result in an increase in the 
number of informative cases and holds potential as a simple routine screen for the 
detection of LOH in the p53 gene (Runnebaum et al, 1994). 
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4.1 INTRODUCTION 
The results presented in Chapter 3 as well as evidence obtained by other workers (Lo 
et al, 1992; Busby-Earle et al, 1994) suggest that p53 mutations may not play an 
important role in tumorigenesis of the cervix. It is therefore relevant to investigate other 
factors implicated in this type of tumour. 
There is a great deal of evidence that viruses, in particular the HPVs, are involved in the 
aetiology of cervical cancer (zur Hausen, 1987; Jenkins, 1994). It is reported that 
different types of HPVs can infect the female genital tract but not all of these are 
associated with progression to malignancy. Thus, depending on the capacity to induce a 
benign lesion or one with malignant potential, HPVs have been classified as low risk or 
high risk (Levine, 1991). Both classes of viruses have a similar genome organization. 
However, the high risk HPV types 16 and 18 encode major transforming proteins E6 and 
E7, expression of which can lead to in vitro immortalization of cell lines (Vousden 
et al, 1991). The E6 and E7 proteins produced by low risk HPV types on the other hand, 
fail to show this property in cells. The E6 oncoprotein encoded by HPV 16 and 18 is now 
known to bind to the p53 tumour suppressor protein to render its inactive, resulting in 
the loss of normal p53 functions within the cell (Werness et al, 1990). The net effect of 
this inactivation may be the same as a somatic mutation in the p53 gene. 
Numerous studies have demonstrated the high incidence of HPV DNA in cervical 
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tumours (zur Hausen, 1987; Riou et al, 1990; Cooper et al, 1991; Das et al, 1992). Thus 
the purpose of this part of the study was to establish the incidence of HPV infection in 
the tumours already examined for LOH of the p53 gene and to compare these data. 
Several different methods have been used for the detection of HPVs such as Southern 
hybridisation with DNA probes and direct in situ hybridisation (ISH) (Blomfield, 1991; 
Cooper et al, 1991). These methods, however, sometimes lack sensitivity and specificity. 
The technique used for the detection of HPV DNA in this study addresses these 
shortcomings by first amplifying the HPV DNA using consensus primers, followed by 
Southern hybridisation with probes specific for the various HPV types. 
4.2 AMPLIFICATION OF HPV DNA USING PCR 
PRINCIPLE 
Since HPV DNA may not be present in tumours in abundant amounts, a region in an 
open reading frame which is common to all HPV types is amplified to provide sufficient 
DNA on which analyses can be made. The common region generally used is the 
conserved HPV protein coat gene Ll, which is targeted for amplification by a set of 
consensus primers that are able to amplify a wide range of HPV types. This is possible 
by the substitution of different bases in the primers to render them degenerate. The level 
of degeneracy is such that the primers are complementary to the DNA of all so far 
sequenced HPV genomes (Chetsanga et al, 1991). In rare cases in which viral integration 




The DNA from 98 of the 101 patients on whom LOH studies were performed was 
included in this study. The remaining 3 were not analysed because of insufficient tumour 
DNA 
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Po"fymera.r;e chai.n reaction 
The general principle and factors influencing the PCR are outlined in Chapter 2. In the 
present chapter details of the protocol to amplify HPV DNA are provided. 
The primers and reaction conditions were those described by Manos et al (1989) and 
Resnick et al (1990). The primers have the following sequences: 
Primer 1 (MYll) 
5' GCMCAGGGWCATAAYAATGG 3' 
Primer 2 (MY09) 





Primer 1 is a sense strand sequence which binds to the complementary antisense DNA 
strand running from 3' to 5'. Primer 2 is an antisense sequence and binds to the 
complementary sense DNA strand runnjng from 5' to 3
1
• These primers are degenerate 
at the positions indicated, at which one or other nucleotide is substituted to render them 
complementary to the DNA of different HPV types. 
The amplified DNA fragment expected is approximately 450 bp in length and is common 
to all known HPV types, as well as to several undetermined types. 
All primers were synthesized on a Milligen Oligonucleotide Synthesizer m the 
Department of Biochemistry at the Unjversity of Cape Town. 
PCR procedure 
Tumour DNA from the patients m this study was amplified as follows: 
Each PCR reaction contained 16 µl DNA (ranging from 9 ng to 75 ng), 5 µl of Taq 
polymerase buffer, 2 mmol/1 MgC1
2
, 1 µmol/1 of each primer, 200 µmol/1 of each dNTP, 
and 1.25 units of Taq polymerase made up to a final volume of 50 µl with sterile 
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deionized water. The mixture (excluding DNA) was then aliquoted to each reaction tube 
using a positive displacement pipette. 
The DNA was boiled for 10 min and quickly chilled on ice prior to being added to the 
PCR mixture. After spinning briefly a few drops of mineral oil were added to each tube. 
Silica gel was used in the heating block holes to ensure good thermal contact. Each run 
included a reaction mix without DNA to monitor for contamination of reagents. 
The PCR was carried out in a Hybaid
®
DNA Thermal Cycle (Hybaid Ltd, UK) for 35 
cycles of: 
93°C for 1 min (denaturation) 
55°C for 1 min (annealing) 
72°C for 1 min ( extension) 
A final 5 min extension at 72°C completed the reaction. 
PCR control 
Human papillomavirus DNA may not be present in every tumour sample analyzed, and 
the use of a control PCR is therefore essential to monitor the integrity of the DNA 
analysed and to check for the presence of inhibitors of the PCR. The control is usually 
a pair of primers which amplify a single-copy human gene that is certain to be present 
in the sample. In this case a pair of primers which amplify the ,8-globin gene was used. 
The PCR product of the control primer needs to be sufficiently different in size from 
that of the target product to enable a clear distinction between the two bands. 
The concentration of the reagents and the cycling conditions for the amplification of the 
.B-globin gene were the same as for the HPV amplification, with the exception that a 
lower primer concentration (100 nmol/1 of each primer) was used. 
The ,8-globin primer sequences are as follows: 
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Primer 1 (GH20) 
5' GAAGAGCCAAGGACAGGTAC 3' 





The expected PCR product is 300 bp. 
Analysis of PCR product 
A 5 µl aliquot of the PCR product was electrophoresed on a 2% agarose gel at room 
temperature for 1 h at 100 V. The molecular weight marker VI (Boehringer) was also 
included on the gel. Following staining with ethidium bromide, a band of 300 bp which 
corresponds to the t,-globin product and a band of 450 bp representing HPV 
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Fig 4.1. Agarose gel (2%) showing the PCR product of HPV amplification and /3-globin amplification. Lane 
1, molecular weight marker VJ (Boeluinger); lane 3, HPV amplification in sample IT; lane 4, absence of HPV 
amplification in sample 3T; lane 4 /3-globin amplification in sample IT; lane 7, {3-g/obin amplification in 
sample 3T. 
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Initially primers for both HPV and ,8-globin amplification were included in the same 
PCR mixture. In some reactions however, inhibition of amplification apparently occurred 
in the presence of both sets of primers (lane 7, Fig 4.2). Thereafter separate PCR 
reactions were carried out for each set of primers, ,8-globin amplification being 
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Fig 4.2. Agarose gel (2%) showing the amplificatio11 of HPV and {J-globi11 DNA. Lane 1, molecular weight 
marker VT (Boehri11ger); lane .Z HPV amplification in sample IT; lane 3, absence of HPV amplification in 
sample 2T; lane 4, HPV amplification i11 sample 4T; lane 5, HPV and {J-globi11 amplificatio11 in sample IT; 
lane� {J-globi11 amplification in the absence of HPV amplification in sample 2T; lane 7, absence of both HPV 
and {J-g/obi11 amplification in sample 4T. 
Precautions taken during PCR procedure 
Precautions taken during the PCR procedure were the same as those described in 
Chapters 2 and 3. Despite these precautions the use of cloned DNA control material 
gave rise to some difficulties. Because of the extreme sensitivity of the PCR technique 
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to contamination by minute amounts of template, previously amplified products or cloned 
DNA which are easily spread by aerosol can present a serious problem when amplifying 
samples (McCance and Hollingworth, 1990), as is seen in Fig 4.3. 
1 2 3 4 5 6 7 
Fig 4.3. Agarose gel (2%) showing intense smearing believed to be due to contamination with cloned DNA. 
Lane 1, molecular weight marker VI (Boel11i11ger); Jane .Z no DNA control; lanes 3 to 7, HPV amplifications 
of d1ff erent samples. 
This contamination was successfully eliminated only by vigorous decontamination 
procedures including UV irradiation of all pipettes, racks and similar equipment, and the 
disposal of all reagents in use at that time. 
The use of cloned HPV DNA as a control for HPV types is therefore not advisable on 
a regular basis (A. Williamson, personal communication) and it is recommended that to 
avoid recurrent problems of contamination these controls are used only once in order 
to verify PCR product. 
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4.3 HPV TYPE IDENTIFICATION USING SOUTHERN ANALYSIS 
Agarose gel electrophoresis of the amplified product, followed by ethidium bromide 
staining merely allows visualization of the PCR product. It is therefore always necessary 
to confirm the presence of the target-DNA and in this case to identify the specific HPV 
type. This was performed by Southern analysis using specific non-radioactively labelled 
oligoprobes. 
PRINCIPLE 
The principle and procedures of Southern blot analysis have been discussed previously 
(Chapters 2.3 vi and 3.3 iii). Slight modifications to the procedure were made because 
of the use in this instance of small synthetic nucleotide probes as opposed to large DNA 
probes. 
ii METHOD 
The probes used to confirm the presence of HPV and to identify the HPV type were 
oligoprobes which were a gift from Dr Anna-Lise Williamson (Dept of Medical 
Microbiology, University of Cape Town). 
* Generic probe.
This probe detects DNA from the common Ll region of the HPV, the presence 
of which indicates infection by one or more types of HPV. The sequence is as 
follows: 
5' CTGTTGTTGATACTACACGCAGTAC 3' 
* Type specific probes for HPV 16 and HPV 18.
Each of these type specific probes recognises a region that is unique to the 
correspondent HPV type. The sequences of these probes are: 
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HPV 16 (MY14) 
5'CATACACCTCCAGCACCTAA3' 
HPV 18 (WD74) 
5' GGATGCTGCACCGGCTGA 3' 
All probes were labelled with a 3' End Labelling Kit (Boehringer) according to the 
manufacturer's instructions. The transfer of DNA to nylon membranes, hybridisation and 
visualization are described in detail in Chapter 2.3 vi. Briefly, the blotted membranes 
were hybridized in Bijou bottles for 1 h at 5 5 °C in 2.5 ml of hybridisation buffer 
containing 5 µ.l of labelled probe. After hybridisation the filters were washed and the 
membranes exposed to 10 ml of a colour reactant to allow development of a visible blue 
precipitate, the presence of which indicates successful hybridisation to a particular HPV 
probe. 
iii RESULTS 
Of the 98 cervical tumour DNA samples amplified using consensus primers, 78 (80%) 
exhibited a PCR product while 20 (20%) did not show any evidence of amplification. 
These 20 samples were also analysed for the presence of the ,8-globin gene to ensure that 
there were no inhibitors present and that there was amplifiable DNA. All 20 DNA 
samples showed amplification of the ,8-globin gene. 
The presence of HPV DNA was confirmed in all 78 samples demonstrating amplification 
by the successful hybridisation with a generic HPV probe. In 76 samples (97%) the HPV 
DNA was typed as HPV 16 and in 6 (8%) samples as HPV 18. Four tumours were found 
to contain DNA for both HPV 16 and HPV 18. 
No evidence of HPV infection was found in tumours 95 and 107, both of which were 
previously shown to have LOH of the p53 gene (Fig 4.4). 
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Fig 4.4. Nylon blots showi11g hyb1idisatio11 of ge11e1ic, HPV 16 a11d 18 DNA probes. Tumour 63, positive for the 
generic HPV a11d both HPV 16 and HPV 18; tumours 64, 96 and 108, positive for 011ly the ge11eric and the HPV 
16 probe; tumours 95 and J(fl 110 evidence of HPV infection. 
4.4 DISCUSSION 
INCIDENCE OF HPV INFECTION 
The 80% incidence of HPV 16 and/or HPV 18 infection in the cervical tumours in this 
study is in concordance with other reports of a 79% to 98% incidence (Riou et al, 1990; 
Higgins et al, 1991; Das et al, 1992; Arends et al, 1993). There are however some studies 
which indicate a slightly lower frequency in the range of 65 to 70% (Cooper et al, 1991; 
Hagmar et al, 1992). In this study the HPV 16 was found to be the more prevalent HPV 
type in squamous cervical tumours which is also in agreement with findings reported in 
the literature. 
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The reasons for the variations in reported frequencies of HPV in cervical tumours are 
unclear. One reason could be the lack of sensitivity and specificity of some of the earlier 
methods which were based on cytological and histological identification of HPV in 
cervical smears (Chetsanga et al, 1991) and later methods which detected HPV by 
Southern hybridisation. Nowdays sensitivity has been improved by the use of PCR to 
detect even very small amounts of HPV DNA and specificity is increased by the use of 
oligonucleotide probes under stringent hybridisation conditions. Another possible 
explanation could be variations in patterns of social behaviour between study groups. 
Since HPV is a sexually transmitted virus, its frequency in sexually promiscuous groups 
may be expected to be higher (Blomfield, 1991). A further reason could relate to the 
disease stage at which tumours were biopsed, since is known that HPV plays a role in 
the early intraepithelial stages of tumour progression but that viral DNA sequences can 
be lost at later stages (Riou et al, 1990). 
In this study the method employed is the same as that being used in several centres 
worldwide and is reported to be both sensitive and specific. Further precautions were 
taken by the inclusion of a control PCR to eliminate the possibility of inadequate DNA 
template and /or PCR inhibitors. 
ii RELATIONSHIP OF HPV TO LOH IN THE p53 GENE 
The most striking feature to emerge from this study was the fact that neither tumours 
which exhibited LOH of the p53 gene had any evidence of HPV infection. This finding 
clearly supports the hypothesis that in the absence of HPV infection somatic mutations 
of the p53 gene may contribute to cervical carcinogenesis, and is in complete accord with 
the observations of Crook et al (1991), Busby-Earle et al (1992), Crook et al (1992), 
Kaelbling et al (1992) and Paquette et al (1993). All these workers consistently reported 
higher rates of p53 abnormalities in HPV negative tumours when compared with HPV
positive tumours. However the study groups were small, ranging between about 20 and 
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42 patients each. The current study examined 101 cervical tumours of which the HPV 
status was known in 98% of cases. 
As mentioned previously (Chapter 3.4 i), the two tumours manifesting LOH which have 
now been shown to be HPV negative have a high probability of harbouring a p53 
mutation. They were therefore screened for mutations by single strand conformational 
polymorphism (SSCP) analysis together with the other tumours which did not contain 
HPV. The results are presented in the next chapter. 
The converse to these findings is that none of the 78 tumours which were found to 
contain DNA for HPV 16 and/or 18 showed any evidence of p53 mutation as determined 
by LOH studies. It is therefore more likely that any p53 involvement in these tumours 
is through viral oncoprotein inactivation of the normal p53 protein. In the future it is 
intended to confirm these findings by screening all the HPV positive tumours for the 
absence of p53 mutations using SSCP analysis. 
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5.1 INTRODUCTION 
Single strand conformational polymorphism is reported to be a convenient and rapid 
method for the detection of mutations (Newton and Graham, 1994a). It was therefore 
decided to use this technique to examine the two tumours which demonstrated LOH 
of the p53 gene for evidence of mutations. In addition, since reports in the literature 
indicate that tumours which do not contain HPV are more likely to carry p53 
mutations (Crook et al, 1991; Scheffner et al, 1991), most of the HPV negative tumours 
identified in this study were also examined for mutations using this technique. Exons 
5, 6, 7 and 8 were selected for screening as more than 90% of the p53 mutations in 
human cancers are believed to occur in well conserved regions of these exons 
(Hollstein et al, 1991). 
The original SSCP protocol makes use of radiolabelled PCR primers to generate a 
product sensitive enough to allow visualisation of the single stranded fragments (Orita 
et al, 1989). This approach, however, is both expensive and cumbersome. In a move 
away from the use of radioisotopes, the technique chosen for this study was a rapid 
'cold' SSCP analysis in which unlabelled PCR primers were used and the single 
stranded DNA fragments were visualized on polyacrylamide gel using ethidium 
bromide (Hongyo et al, 1993). 
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5.2 PCR-SSCP 
i PRINCIPLE 
The principle of SSCP has already been discussed in Chapter 2. Briefly, this technique 
depends upon the fact that under non-denaturing gel conditions, single-stranded DNA 
molecules fold into unique conformations which are determined by their nucleotide 
sequence. Thus by comparison of differences in mobility of wild-type (normal) and 
mutation-bearing single strand DNA fragments through a solid support, such as 
polyacrylamide gel, different patterns can be visualised with the aid of radioisotopes, 
ethidium bromide, silver nitrate or chemiluminescence (Orita et al, 1989; Hongyo et 
al, 1993; Faille et al, 1994; Niwa et al, 1994). Evidence of a mutation is usually defined 




The two cervical tumours (95 and 107) which showed evidence LOH of the p53 gene 
were subjected to PCR-SSCP analysis. A further 16 tumours were included in the 
analysis, none of which had any evidence of HPV infection. In addition, DNA from a 
breast tumour (3T) in which LOH had been demonstrated previously, was included. 
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DNA control 
DNA samples from two HPV negative cervical cancer cell lines, HT3 and C33A, 
known to carry point mutations in exons 7 (codon 245) and 8 (codon 273), respectively, 
were also analyzed. These were a gift from Dr Tim Crook of the Rayne Institute, 
Kings College School of Medicine, London. 
Polymerase chain reaction 
As mentioned previously the first step in the preparation of DNA for analysis by SSCP 
is amplification of the region of interest. The general principle and the factors 
influencing the PCR are outlined in Chapter 2. In the present chapter the protocols 
used to amplify exons 5 to 8 of the p53 gene are described in detail. 
a Design of the primers 
Although numerous publications are available describing procedures for PCR­
SSCP analysis of the p53 gene, there is little uniformity on the sequences of the 
primers used or explanation as to the choice of these sequences. This made the 
selection of primers difficult. It was therefore decided to choose primers for this 
study based on the following specific criteria (Bangham, 1991): 
*
* 
Similar primer pair length (18-21 bases) and composition, so that Trns
are within 5°C of each other.
Similar GC content for both primers (ideally 50-60% ).




No self-complementarity or complementarity with the other primer. 
No runs of three or more Gs or Cs at the 3' end of the primer. 
Amplified product not greater than 300 bp in size. 
* Primer sequences selected flanking introns so that the complete exon
sequence is included in the PCR product.
The primers were synthesized on a Gene Assembler (Pharmacia, LKB 
Biotechnology, Sweden) in the Faculty of Medicine Molecular Biology Unit of 
the University of Natal. 
The sequences of each primer pair are shown below: 
Exon 5 bp A+T G+C Tm GC% 
5'TCTGTTCACTTGTGCCCTGAC3' 21 10 11 64 52 
5' ATCAGTGAGGAATCAGAGGC 3' 21 10 11 64 52 




..................... acgacagggctggttgcccagggtccccaGGCCTCTGA TTCCTCACTGAT 
The expected size PCR product is 308 bp. 
Exon 6 bp A+T G+C Tm GC% 
5' AGAGACGACAGGGCTGGTT 3' 19 8 11 60 58 
5' AAAGCCCCCCTACTGCTCA 3' 19 8 11 60 57 
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The expected size is 259 bp. 
Exon 7 bp A+T G+C Tm GC% 
5' AAAAAAGGCCTCCCCTGCTIG 3' 21 10 
5'GGTGGATGGGTAGTAGTATGG3' 21 10 
These primers flank the following region in exon 7: 
13924-+ 
11 64 52 
11 64 52 
AAAAAAGGCCTCCCCTGCTIGccacaggtctccccaaggcgcactggcclcatcttg ............ . 
-14222
.............. tgacccctgggcccacctcttaccgatttcttCCATACTACTACCCATCCACC 
The expected size is 298 bp. 
Exon 8 bp A+T G+C Tm GC% 
5' GGACCTGATITCCTTACTGCC 3' 21 10 11 64 52 
5' TGCACCCTIGGTCTCCTCCA 3' 20 8 12 64 60 
These primers flank the following region in exon 8: 
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14402-
GGACCTGA TITCCTT ACTGCCtcttgcttctcttttcctatcctgagtagtggtaa tct. ............ . 
-14632
............. aagcaagcaggacaagaagcggTGGAGGAGACCAAGGGTGCA 
The expected size is 231 bp. 
b Annealing temperature and cycling conditions 
All primers have similar Tms which allowed the use of the same annealing 
temperature to amplify exons 5, 6, 7 and 8. After an initial denaturation step 
at 94°C for 5 min, each reaction mix was subjected to 30 cycles at the following 
temperatures: 
94°C for 1 min (denaturation) 
59°C for 1 min ( annealing) 
72°C for 1 min ( extension) 
A final 10 min extension at 72°C completed the reaction. 
c PCR procedure 
Each reaction contained 16 µl DNA (approximately 9 to 75 ng), 5 µl of Taq 
polymerase buffer, 2 mmol/1 MgC12, 200 nmol/1 each primer, 200 µmol/1 
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dNTPs and 1.5 units of Taq DNA polymerase made up to a final volume of 
50 µl with sterile deionized water. The exact procedure followed to set up the 
reaction was the same as that described in Section 3.2 iii. 
The DNA was boiled for 10 minutes and quickly chilled on ice prior to being 
added to the PCR mixture. After spinning briefly a few drops of mineral oil 
were added to each tube. The reaction mixes were then subjected to the cycling 
conditions described above. Each run included a reaction mix without DNA to 
monitor for contamination of reagents. 
d Precautions taken during the PCR procedure 
The precautions taken to avoid contamination in the PCR were the same as 
those described in Section 3.2 iii. 
e Identification of the PCR products 
A 6 µl aliquot of the PCR product mixed with 1.5 µl of loading buffer (0.25% 
bromophenol blue, 40% sucrose, 1 mg/ml of ethidium bromide made up to 
2 ml with 0.5 x TBE) was loaded on to a 2% agarose gel (as described in 
Section 2.3 iii). The gel was electrophoresed at room temperature for 1 h at 
90 V. A molecular weight marker (Hinfl-Promega) was included in each gel. 
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The successful amplification of each exon was confirmed by the identification 
of a band of the appropriate base pair size (Fig 5.1). The presence of 
unambiguous bands made purification of the PCR product unnecessary. 
1 2 3 4 5 
Fig 5.1. Agarose gel (2%) showing the amplification products of the various exons. Lane 1, 
amplification product (308 bp) of exon 5; lane .Z amplification product (259 bp) of exon 6; lane 3, 
molecular weight Hinfl (Promega); lane 4, amplification product (298 bp) of exo11 7; lane 5, 
amplification product (231 bp) of exon 8. 
f Optimization of the PCR 
All 4 exons amplified satisfactorily in the first instance under the conditions 
described above. It was therefore unnecessary to carry out extensive 
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optimization procedures. Slight adjustments were however made to the 
annealing temperature to eliminate minor non specific bands. 
SSCP analysis 
As suggested in Chapter 2 (Section 2.3 vii) several factors are critical for successful 
SSCP analysis. Each of these was addressed carefully in an attempt to obtain optimal 
separation of the single strands. The final validated procedures are presented below. 
a Denaturation of the PCR product 
A mixture consisting of 5 µ1 of PCR product, 1 µ.l of loading buffer (0.25% 
bromophenol blue, 0.25% Xylene-Cyanol, 30% Ficoll in 1 x TBE buffer), 
13.6 µ.l of 1 x TBE and 0.4 µ1 of 1 mol/1 NaOH was prepared to yield a total 
volume of 20 µI. This was heated at 98°C for 5 min and then immediately 
placed on ice prior to loading the entire 20 µ.l on to the gel. 
Adequate denaturation of the PCR product was vital to the detection of single 
strand bands. It was found that in the presence of an insufficient amount of 
NaOH, only the double stranded product was visualized (results not shown). 
b Electrophoresis conditions 
A 10% polyacrylamide mini gel (8 cm x 8 cm x 0.75 mm) containing 4% 
glycerol was used. This was made as described in Section 2.3 iii. The buffer 
chamber of the electrophoresis apparatus was filled with 1 x TBE buffer and 
the apparatus was connected to a thermostatically controlled circulating water 
bath (Ephortec™ , Haake Buchler Instruments, Inc. Saddke Brook, NJ), to 
maintain a constant temperature during electrophoresis. 
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After loading the gel with the PCR mixture prepared as described above, 
electrophoresis was carried out at 300 V at the temperature appropriate for the 
exon being examined, until the bromophenol blue marker reached the bottom 
of the gel. The running time was approximately 45 min. 
A polyacrylamide gel of 10% was found to give the sharpest bands under the 
electrophoretic conditions described above (results not shown). 
c Temperature 
Each exon required a different temperature which was determined empirically, 
for optimal separation of the single stranded fragments. The optimal 
temperatures were determined as 27°C for exon 5, 14°C for exon 6, 15°C for 
exon 7 and 4 °C for exon 8. 
d Visualisation and documentation 
The polyacrylamide gel was stained with a 0.5 µg/ml solution of ethidium 
bromide in 1 x TBE for 20 min, and then destained in distilled water for 5 min 
and documented as described in Section 2.3 iii. 
iii RESULTS 
SSCP analysis 
Each of the four exons examined showed two single strand bands on PAGE under the 
conditions described above (Fig 5.2a,b ). These bands represent the normal or wild-type 
single strand conformations. Samples of DNA carrying known mutations in exons 7 
and 8 (HT3 and C33A, respectively) clearly demonstrated band shifts on SSCP analysis 
of the appropriate exon (Fig 5.2b). No DNA with mutations in exons 5 or 6 was 
available for validation. 
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Fig 5.2a. Polyac,ylamide gel ( 10%) showing single strand fragments of exons 5 and 6 following amplification 
by PCR. Doubled stranded DNA is indicated by DS. The numbers on each lane indicate blood (B) or 
tumour (T) DNA from patients with cervical tumours. 
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Fig 5.2b. Polyacrylamide gel ( 10%) showing single strand fragments of exons 7 and 8 following amplification 
by PCR. Note the distinct band shifts in samples HT3 (lane 7) and C33A (lane 4) which contain known 
mutations in erons 7 and 8, respectively. Double stranded DNA is indicated by DS. 17,e numbers on each 
lane indicate blood (B) or tumour (T) DNA from patients with cervical tumours. 
The temperature at which each exon was subjected to PAGE was found to be critical 
to within one or two degrees. This can be seen in Fig 5.3, in which the upper single 
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strand of exon 6 appears to have an alternative conformation at a suboptimal 
temperature (12°C). At 14°C only two single strand bands are visible. This 








1 2 3 4 5 6 7 8 9 10 
Fig 5.3. Polyac,ylamide gel (10%) showing different co11fonnatio11s of exon 6 following PAGE at 17'C and 
14°C. Note tlzat the same PCR product from tumours 21, 55, 110, 113 and 95 was nm on each gel. 
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Detection of mutations 
No evidence of mutations as determined by band shifts or additional bands in exons 
5, 6, 7 or 8 of the p53 gene was detected in either of the two tumours (95 and 107)
which demonstrated LOH of the p53 gene. Neither was there evidence of mutations 
in any of the 16 HPV negative cervical tumours. 
The DNA from a breast tumour (3T) which was included in the SSCP analysis because 
it demonstrated LOH, was found to exhibit a slight shift downwards in both bands of
exon 5 (Fig 5.4). 
EXON 5 
1 2 3 4 5 6 
Fig 5.4. SSCP analysis of exon 5 which shows downward band shifts of both single strand fragments from 
the breast tumour (3T) in lanes 1 and 2 when compared with wild-type in lanes 3 and 4. 
Detections of m11tatio11s by PCR-SSCP 101 
5.3 DISCUSSION 
i METHODOLOGY 
The conventional approach to PCR-SSCP analysis as first described by Orita et 
al (1989) made use of radio-labelled primers and large formatted polyacrylamide gels, 
which allow good resolution and sensitive detection of single strand fragments. 
Recently however, there have been attempts to move away from the use of isotopes 
with the introduction of chemiluminescence, silver nitrate and ethidium bromide for 
the detection of single strand fragments (Hongyo et al, 1993; Arai et al, 1994; Niwa 
et al, 1994 ). At the same time simplification of the technique in terms of the use of 
readily available and easily handled small polyacrylamide gels has been a convenient 
innovation. The method adopted for use in this study is based on one such approach, 
that of Hongyo et al (1993). 
The primers used for the amplification of exons 5 to 8 were selected specifically for 
this study because on analysis of the literature, ambiguities were found in a number 
of the published primer sequences and it was deemed advisable to apply the same set 
of criteria to the choice of all primers. The primers selected appear to have been 
satisfactory with respect to the PCR product obtained since all 4 exons amplified, 
resulted in clear unambiguous bands. 
Under appropriate conditions the analysis by SSCP of the 4 exons yielded two single 
strand bands in each instance. A direct comparison of these bands with those reported 
in the literature was impossible due to the variety of conditions under which SSCP is 
applied. Comparison with the method of Hongyo et al (1993) however, revealed 
apparently similar single strand bands, at least for the exons illustrated. In addition the 
behaviour of the single strand fragments observed in this study, particularly with 
respect to the temperature at which electrophoresis was carried out, was consistent 
with that reported by Hongyo et al (1993). 
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With respect to the two DNA controls for exons 7 and 8, both demonstrated clear 
band shifts, as did the DNA from the breast tumour (3T) in exon 5. The breast tumour 
DNA was sent for analysis to Dr Tim Crook of the Rayne Institute, Kings College 
School of Medicine, London who confirmed band shifts in exon 5 (personal 
communication). This sample was of particular interest because, having been shown 
to have loss of one allele, it would be expected to have only two bands in the 
apparently mutated form, as was found to be the case. Similarly, in view of the fact 
that neither of the two controls showed more than two bands, it seems likely that both 
these cell lines exhibit a 17p LOH. 
Thus the PCR-SSCP technique described here would appear to fulfil the criteria of a 
convenient, economical, rapid (less than two hours), and sensitive method for the 
detection of mutations in the p53 gene, bearing in mind that it is a screening technique 
and not a definitive identification. Potential problems due to factors such as poor 
optimization and inadequate denaturation of the DNA have been addressed. Failure 
of SSCP analysis in some instances could possibly be due to non-controllable factors, 
such as the position and nature of the mutation since this, together with the sequence 
of the fragment being analysed, affects the ultimate conformation assumed and 
consequently the mobility upon gel electrophoresis (Weghorst and Buzard, 1993). 
ii p53 MUTATIONS 
Of a total of 18 HPV negative tumours screened for mutations in exons 5 to 8 of the 
p53 gene, none showed any evidence of a mutation. These results reflect once more 
the apparently low frequency of p53 mutations in cancer of the cervix in Black South 
African women. Only two other studies are reported in which SSCP was used as a 
screen for mutations in HPV negative tumours: Fujita et al (1992) who observed no 
abnormalities in 7 tumours and Park et al (1994) who identified SSCP abnormalities 
in 2 out of 21 tumours. Both these tumours were subsequently confirmed by direct 
sequencing to have missense mutations in exons 5 and 8. In addition Crook 
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et al (1992) showed point mutations by direct sequencing in 3 out of 3 tumours which 
lacked HPV. In a recent publication Park et al (1994) reviewed the literature and 
reported a 15% incidence (6/41) of p53 mutations in HPV negative tumours. In 
contrast, in HPV positive tumours an incidence of only 3% (7 /206) was recorded. It 
is interesting to note that all 13 mutations so far reported in tumours of the cervix, as 
well as the two cell lines, were found in exons 5 to 8. 
It was disappointing that in this study it was not possible to demonstrate evidence of 
p53 mutations on the basis of SSCP mobility shifts in any of the 18 HPV negative 
tumours. This was particularly so in the case of the two tumours which exhibited LOH 
of the p53 gene, a feature associated with mutations in the corresponding allele in over 
80% of tumours (Hollstein et al, 1991). However, it should be borne in mind that this 
study undertook SSCP analysis in exons 5, 6, 7 and 8 only, and the possibility exists 
that there may be mutations present elsewhere in the gene. 
\ 
To address this possibility DNA from tumours 95 and 107 (those showing LOH) was 
sent to Dr Tim Crook of the Rayne Institute for further SSCP analysis. He confirmed 
the absence of any aberrant SSCP bands in exons 5 to 8, but reported mobility shifts 
in exons 2/3 in both these tumours. These findings will in due course be validated by 
direct sequencing (personal communication). 
In view of this communication, it would appear therefore that LOH as detected by the 
PCR based VNTR technique described here does in fact predict the presence of a 
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mutation as assessed by SSCP analysis. This is further substantiated by the 
identification of band shifts in exon 5 of the breast tumour which exhibited LOH. 
If these abnormalities are indeed confirmed by sequencing, this will constitute a very 
interesting finding since all p53 mutations so far reported in cervical tumours are in 
exons 5 to 8 (Park et al, 1994). It is possible that in the Black South African 
population, a novel pattern of p53 mutations exists in tumours of the cervix, and 
perhaps in other tumour types. A similar observation has been reported recently in a 
cohort of Black American breast cancer patients who show a different pattern of p53 
mutations and have a high mortality (Blaszyk et al, 1994 ). 
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CHAPTER6 
CONCLUSIONS 
The primary objective of this project was to undertake a study into the possible 
involvement of the p53 tumour suppressor gene in tumours of the cervix amongst 
Black South African women. A study of this nature is timely, both because the p53 
gene has not been widely researched in this malignancy, and because cancer of the 
cervix is the most prevalent tumour in this population group. 
The results obtained using LOH of the p53 gene as a screen for mutations suggest that 
p53 mutations are not a common event in squamous carcinoma of the cervix since only 
a 4% incidence of LOH was detected in informative tumours. This observation was 
substantiated by the absence of p53 mutations as determined by PCR-SSCP analysis 
in exons 5 to 8 of tumours without any evidence of HPV infection. Abnormalities on 
PCR-SSCP analysis were subsequently shown in exons 2/3 of the two tumours 
exhibiting LOH, which led to the conclusion that LOH of the p53 gene does indeed 
predict the presence of a mutation as assessed by SSCP. These findings reflect reports 
in the literature which indicate a composite 5% incidence of p53 mutations in a total 
of 247 cervical tumours studied (Park et al, 1994); all these mutations occurred in 
exons 5 to 8. 
Thus the results of this study suggest firstly, that the apparent low incidence of p53 
mutations in tumours of the cervix in Black South African women is similar to that 
seen in other populations. Secondly, the two cases of LOH of the p53 in this study 
occurred exclusively in HPV negative tumours, a group which comprised only 20% of 
the total study. This implies that mutations in the p53 gene may not play a major role 
in carcinogenesis of the cervix and that the more significant contributory factor is likely 
to be a viral involvement, probably through the HPV E6 inactivation of the normal 
p53 protein. 
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Thirdly, the presence of SSCP abnormalities in exons 2/3 of the two tumours with 
LOH, suggests that the aetiology of cancer of the cervix involving genetic alterations 
in the p53 gene in Black women, may differ from that in other ethnic groups. 
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